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ABSTRACT 
To date the only standard of care for Hepatitis C virus (HCV) infection is 
combinational therapy of interferon and ribavirin. Interferon based therapy is a treatment 
of long duration, associated with cost-effects and serious side-effects. The struggle for 
discovering new direct-acting antiviral agents (DAAs) against HCV infection is still 
continued. The researchers are making efforts to use combinational therapy against HCV 
without the involvement of interferon. The majority of patients are treated with interferon 
plus weight based ribavirin. Therefore, the present study was designed to search for 
independent markers that may significantly predict the treatment outcomes of interferon 
based therapy of HCV infection in Pakistani population. This study would assist the 
clinic doctors and researchers for personalized treatment of HCV infection. 
Both viral and host factors were considered for the prediction of interferon based 
therapy of HCV infection in the present study. There were recruited 140 chronic HCV 
patients and 120 healthy individuals. In the current study; patient characteristics, single 
nucleotide polymorphisms (SNPs) of important genes, viral genotypes and baseline viral 
load were considered. SNPs of the host genome were studied by allele specific 
polymerase chain reaction (AS-PCR), amplification refractory mutation system 
polymerase chain reaction (ARMS-PCR), and restriction length polymorphism 
polymerase chain reaction (RFLP-PCR). HCV genotyping was performed by Ohno 
method. HCV viral quantification was performed by real time PCR. 
The results showed that HCV genotype 3 was the most prevalent genotype (81%) 
with a very high response rate (91%). The distribution of other HCV genotypes was 
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comparatively less and also showed decreased response rate to interferon based therapy. 
The level of alanine aminotransferase (ALT) and low baseline viral load were linked with 
enhanced response rate to combinational therapy of HCV infection. Regarding SNPs in 
the host genome; SNPs of interleukin 28B (IL28B) clustered RefSNPs (rs) 12979860 and 
rs8099917, IL18 promoter variants, -607C/A (rs1946518) and -137G/C (rs187238), 
oligoadenylate synthetase gene 1 (OAS1) at exon 7 splice accepter site (SAS), 
rs10774671, osteopontin (OPN) -442 C/T (rs11730582), TGF-β1 functional 
polymorphism at codon 10 T/C (rs1982073) and codon 25 G/C (rs1800471), a single 
nucleotide variant in intron 6 of GALNT8 rs10849138 were analyzed for their association 
with natural clearance and interferon based therapy of HCV infection. There was found 
significant associations of IL28B rs12979860CC genotype, OAS1 rs12979860GG 
genotype, IL18 -607AA genotype, OPN -442TT genotype with HCV infection and 
treatment response. In conclusion, HCV genotyping and testing of IL28B polymorphism 
may be used as predictive markers for the outcomes of interferon based therapy in 
Pakistani population. 
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Chapter 1 
  INTRODUCTION 
 Hepatitis C Virus (HCV) was discovered as non-A non-B hepatitis virus in 
1989 that is mostly  transmitted through blood transfusion (Choo et al., 1989). HCV has 
infected 200 million people  around the globe (Davis and Thorpe, 2013). Approximately 
three to four million people are infected with the HCV each year (Zhang et al., 2013). 
HCV prevalence is also very high in Pakistan. About 5.5% of the  Pakistani population is 
infected  with HCV (Waheed et al., 2009). According to US center of disease control and 
prevention, in America each year about 25,000 people are getting HCV infection (Llovet  
et al., 2008). Thus, HCV is not only a serious health problem of developing countries but 
also a major economical and physical burden of developed countries. HCV infection 
leads to either acute or chronic hepatitis.  
 Acute HCV infection is mostly asymptomatic. If the symptoms are present, 
they are not very specific and usually abate within few weeks. Acute HCV infection in 
60-80% leads to the chronic stage. The progress of infection from acute to chronic stage 
is a slow process and may take 20-30 years. Chronic HCV infection is the leading cause 
of liver failure and liver transplantation worldwide (Seeff, 2002). 
HCV is an enveloped positive stranded RNA virus of approximately 9.6 kb 
genome belonging to the family, Flaviviridae. It comprises of four structural and six 
nonstructural proteins. Being RNA virus and lack of proofreading in its RNA polymerase 
enzyme, it possesses eleven genotypes, subgenotypes and quasispecies (Ali et al., 2014). 
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The natural history of HCV infection shows that 20-40% of infected individuals 
spontaneously clear the infection within few months of infection. However, the majority 
of cases are progressed to chronic stage (Kamal, 2008). Thus, HCV infection is a 
complex interplay between host and virus. There are a commendable number of factors 
that intervene and make the treatment complicated. Recent evidence has convincingly 
support this fact that the host and viral factors are key players that determine the response 
rate to interferon based therapy of HCV infection. Interferon therapy of HCV infection 
was used even before the discovery of the virus (Hoofnagle et al., 1986). In the 
beginning, sustained virological response (SVR) was only 6%. SVR is defined as 
undetectable HCV RNA in patient’s serum, six months after the cessation of treatment, 
while in the vice versa situation patients are referred as non responders (NRs). Rapid 
virological responders (RVR) are those patients that possess undetectable HCV RNA at 
week four of treatment. Later on, by increasing the treatment duration to 48 weeks the 
SVR rate was raised to 16% (Di Bisceglie et al., 1989; Davis, 1989). The addition of 
ribavirin to interferon therapy elevated the SVR rate to 42% (McHutchison, 1998; 
Poynard et al., 1998). The discovery of pegylated interferon leads SVR rate to 54-55% 
(Zeuzem et al., 2000; Lindsay et al., 2001; Reddy et al., 2001). Recently, the addition of 
protease inhibitors to combinational therapy has increased the SVR rate to approximately 
74% (Kwo et al., 2010). 
Among the viral factors, HCV genotypes and baseline viral load are important. It 
is suggested that HCV genotypes 2 or 3 should be treated with pegylated interferon and 
ribavirin.  HCV genotype 1 patients should be treated with pegylated interferon, ribavirin 
and protease inhibitor. HCV genotype 4 infected patients should be treated with peg-
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interferon and ribavirin. The treatment duration is mostly dependent on HCV genotypes. 
In general, longer the treatment duration, the lesser the chances of relapse (Gary-Gouy et 
al., 2012). Moreover, the high baseline viral load, mutations in E1-E2, core region, NS5A 
and interferon sensitivity determining region (ISDR) are associated with treatment 
failure. However, the results are conflicting and require further investigations (Manns et 
al., 2001; Wohnsland et al., 2007).  
Among the host factors, patient characteristics and mutations in the genomic 
structures are important. Regarding patients characteristics, younger age, low body mass 
index, low alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), 
alkaline phosphatase (ALP) levels, no other associated diseases, are all positively 
associated with interferon based therapy of HCV infection. Regarding mutations in the 
genomic organization single nucleotide polymorphisms (SNPs) have drawn attention. 
SNPs are considered as the most important host factors in interferon based therapy of 
HCV infection.  
Most of the diseases that badly affected mankind are the result of complex 
interactions of lifestyle, environmental and genetic factors. SNPs may increase or 
decrease the chance of getting a disease. Thus, the genetic testing of disease specific 
SNPs may play a role in estimation of an individual risks of getting a disease and 
treatment outcomes. Although, the genetic testing of disease associated SNPs may only 
indicate a somewhat higher or lower risk of developing a disease, but they may also 
provide valuable information to the individual to make an informed decision about 
precautionary measure such as changing lifestyles or environment. Moreover, if the 
disease specific SNP possessed a role in response to the treatment, then the individual 
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may go for personalized medical therapy. SNPs also give us information about the 
molecular mechanism of a disease. Thus, from the patient point of view, SNPs can 
provide a platform for a more personalized tactic of treatment. From the pharmaceutical 
industrial point of view, SNPs may lead to the new drug targets that would be more 
effective, targeted and better tolerated. In short, understandings about these small genetic 
differences in the human genome are growing all the times. Findings of disease specific 
SNPs are a matter of great interest and a challenge for pharmaceutical industries (Weiner 
and Hudson, 2002). SNPs have a very critical role in population genetics, drug 
development, forensic and genetic diseases (Stoneking, 2001).  
Recently genome wide association studies (GWAS) have shown that SNPs in the 
vicinity of IL28 are important in spontaneous clearance and response to interferon based 
therapy of HCV infection (Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009; 
Rauch et al., 2010). However, the role of IL28B in HCV genotype 2 and 3 is still 
controversial. Therefore, IL28B genotyping test is part of the standard of care against 
HCV genotype 1 only (Bellanti et al., 2012). Genetic variations of different host and viral 
genes against HCV pathogenesis in various ethnic groups are also reported to possess a 
significant influence on natural clearance and response to interferon based therapy of 
HCV infection (Imran et al., 2013a). 
In Pakistan, HCV is a major health concern because 75% of patients do not 
receive standard anti HCV therapy (Interferon + Ribavirin) and the 25% that receive the 
treatment, the SVR rate is 60-70%.  HCV patient’s varied treatment response is among 
one of the major obstacle regarding HCV management. Combination of interferon (IFN) 
with various formulations (most commonly ribavirin) is the only approved therapy by 
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food and drugs administration (FDA) for chronic HCV patients. The treatment is 
currently considered as a standard treatment, but it is both physical and economic burden 
for the patients. Therefore, the current study was designed to search for some biological 
markers that can significantly predict the response rate to interferon based therapy of 
HCV infection. Such potent biological markers would help the clinical doctors to take 
informative decision regarding patient treatment. Present study scrutinized 140 chronic 
HCV patients and 120 healthy controls. Both viral and host factors were considered for 
their role in the combinational therapy (interferon + ribavirin) of HCV infection. From 
viral point of view, baseline viral load and viral genotypes were considered. While 
regarding host factors, important SNPs were investigated for their association with 
treatment response. 
To the best of our knowledge, there is no study from Pakistan or neighboring 
country that has analyzed SNPs of these critical factors for interferon based therapy of 
HCV infection. The study would assist the search for such viral and host factors that will 
predict the success or failure of standard IFN therapy response in chronic hepatitis C 
(CHC) Pakistani patients. Taken together, the findings of current study suggest that HCV 
genotypes, SNPs of IL28B, IL18, OAS1 and OPN are potential significant predictors of 
treatment response in chronically infected HCV patients. Furthermore, low baseline viral 
load and ALT levels were also positively associated with the response to interferon based 
therapy of HCV infection in local population. This study would benefit the patients to be 
saved from the adverse side effects of interferon based therapy of HCV infection. Patients 
would also be saved from cost effects of interferon plus ribavirin treatment. Moreover, 
Chapter 1                                                                                                          Introduction                                                                                                                     
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  6 
 
those patients possessing more chances of treatment failure may seek for alternative 
treatment options of HCV infection. The main objectives of the current study were: 
 Blood sampling of chronic HCV patients that are undergoing interferon based therapy of 
HCV infection from provinces, Sindh and KPK of Pakistan  
 Follow up of the enrolled chronic HCV patients up to the six months after the end of 
therapy. 
 Determining the genotypes of chronic HCV patients. 
 Genetic testing of host genomes of all enrolled subjects for exploring the correlation of 
important genetic variations (9 SNPs) with interferon based treatment of HCV infection. 
 Analysis of viral and host factors with interferon based therapy of HCV infection. 
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Chapter 2 
REVIEW OF LITERATURE 
2.1 HISTORY OF HCV  
Long time ago, it was believed that jaundice is the result of divine punishment. 
There occurs imbalance of body humours due to environmental factors leading to skin 
discoloration, but this opinion was turned down by Hippocrates in 400 BC. For the first 
time, Jaundice was associated with the liver inflammation and named the hardening 
feature of the liver as "kirrhos". Since the 17th century, there occurred multiple outbreaks 
of jaundice. The epidemic outbreaks of the disease suggested that it causes an infectious 
etiologic nature. In 1908, it was suggested that the virus may be the cause of fulminant 
hepatitis (White, 1908). 
In 1967, there were discovered two types of clinical hepatitis; one was associated 
with fecal oral transmission while the other was associated with blood transfusion. This 
leads to the discovery of hepatitis B (Dane and Cameron, 1970) followed by hepatitis A 
(Feinstone et al., 1973). However, it was revealed by the retrospective study of stored 
sera that neither of these two viruses was responsible for blood transfusion associated 
hepatitis. This search for infectious etiology of non-A, non-B hepatitis (NANBH) leads to 
the discovery of Hepatitis C (Prince et al.,1974). HCV was first cloned from a cDNA 
library of NANBH cases by Choo et al in 1989 (Choo et al., 1989). The recombinant 
peptide consists upon about 10,000 nucleotides. Later on, the recombinant peptide was 
used to capture antibodies from the sera of NANBH cases confirming the presence of 
HCV in these patients. 
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2.2 HCV EPIDEMIOLOGY 
HCV is a major health problem affecting nearly 200 million people worldwide. 
HCV is the most prevalent in Egypt (22%) (Frank et al., 2000). The highest rate of HCV 
prevalence in Egypt is mostly attributed to parenteral anti-schistosomal therapy (Choo et 
al., 1989). In the United States of America approximately, 1.8% of people are positive for 
HCV antibodies while 2.7 million people have an active HCV infection. In Northern 
Europe, HCV prevalence is 0.3%, while in Southern Europe and North America its 
prevalence is 1.5%. HCV prevalence in sub-Saharan Africa is 3% (Madhava et al., 2002). 
In Pakistan, the overall prevalence of HCV is 6%, but there may be small pockets of high 
HCV prevalence e.g. HCV prevalence in Gujranwala and Lahore is approximately 23.8% 
and 15.9% respectively (Hamid et al., 2004). 
2.3 ROUTES OF HCV TRANSMISSION 
Approximately 50% of HCV transmission cases are attributed to unknown routes 
(Memon, 2002). The main route of HCV transmission before 1990 was blood transfusion. 
However, since 1990 the blood screening for HCV antibodies has significantly reduced 
transfusion related HCV transmission particularly in Asian countries. Currently, the main 
route of HCV transmission is the use of intravenous drugs. The average prevalence of 
HCV among the intravenous drug users is 80% (Sulkowski,1998). In Pakistan, there are 
about 5 million drug users, 15% of them are regular IDU (United Nations Office for Drug 
Control and Crime Prevention, 2002). In Pakistan, the main drug is heroin. Heroin is a 
common inhalation drug in Pakistan and Afghanistan. As the availability and quality of 
heroin is gradually decreasing, so therefore most of the drug users switched from 
inhalator to injectable drugs. The injectable drugs are comparatively more intensive and 
Chapter 2  Review of Literature 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  9 
 
satisfying. In Pakistan, the prevalence of HCV infection among drug users in is 57% ± 
17.7% (Achakzai et al., 2007;  Altaf et al., 2009; Platt et al., 2009). The distribution of 
HCV infection among thalassemia and hemophilia population is 8.67% ± 1.75% (Arif et 
al., 2008). 
Health care workers are at the most high risk of HCV transmission. HCV 
transmission in health care worker mostly occurs by needle stick injuries during 
recapping of syringes. It is reported that HCV transmission among health care workers 
ranges from 2% - 10% (Hamid et al., 1999). HCV may also be transmitted by sexual 
contact. A report from USA showed that 20% of new cases of HCV infection were due to 
sexual contact (Alter et al., 1999). Saliva can also be the source of virus transmission. 
Polymerase chain reaction (PCR) also revealed that HCV was detected in the saliva of 
infected patients. It is still to be determined that the low quantity of virus particles which 
were detected in the saliva, has the sufficient potential to cause infectivity (Ferreiro, 
2005). The other minor routes of HCV transmissions are sharing of tooth brushes, reuse 
of syringes and needles (Simonsen et al., 1999; Khan et al., 2000). Approximately, 2 
million people are annually HCV infected by contaminated health care injections that 
contribute for almost 40% in distribution of HCV infection worldwide (Simonsen et al., 
1999). In developing countries, the re-use of razors by barbers  also majorly contribute in 
distribution of HCV infections (Janjua and Nizamy, 2004). 
2.4 HCV GENOME AND STRUCTURE 
HCV is a positive stranded RNA-virus which is translated into a single precursor 
polypeptide chain of about 3300 amino acids. It is very heterogeneous as its nonstructural 
protein; NS5B, RNA-dependent RNA polymerase (RdRp) is prone to mutation. There are 
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eleven major genotypes of HCV (Safi et al., 2012). These genotypes are determined on 
the basis of their nucleotide variations up to 35%. There are also many sub-types of HCV 
which are based on their sequence variability up to 25%. RdRp has a lack of proof 
reading, therefore there are also many quasi-species of HCV. HCV genotypes are 
important predictors of treatment response (Simmonds et al., 2005; Nakano and 
Sugiyama, 2012). 
HCV genome comprises 5'-untranslated region (UTR) containing an internal 
ribosome entry site (IRES) and an open reading frame (ORF) with four structural proteins 
(Core, E1, E2 and P7) and six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A 
and NS5B). At the end of the polypeptide chain there is 3' UTR (Moradpour et al., 2007; 
Poenisch and Bartenschlager, 2010). The binding site of liver specific MicroRNA-122 
(miR-122) is present in 5' UTR  as shown in Figure 1 (Jopling et al., 2005). 
 
 
 
 
 
 
 
 
 
Figure 1.1: HCV genome organization and its proteins. Adapted from Moradpour et al., 
2007. 
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HCV virions have not yet been visualized definitely; however, electron 
microscopy revealed that its size is 40-70 nm in diameter (Wakita et al., 2005). These 
virions are tightly associated with lipoproteins. It has been shown that multiple copies of 
core having genomic RNA and E1, E2 glycoproteins are anchored with the lipid bilayer 
that is derived from the surrounding cells (Andre et al., 2005). 
2.5 HCV LIFE CYCLE 
2.5.1 Virus Entry 
The first step of the virus life cycle is its entry into the host cell. HCV has a 
narrow range of host, from chimpanzee to human. The ultimate target of the virus is 
hepatocytes, but the virus is also reported in B lymphocytes, dendritic cells and 
endothelial cells (Fletcher et al., 2012). The host receptors that are associated with virus 
entry into the cells involve CD81 (Pileri et al., 1998), LDL receptor (Agnello et al., 
1999), scavenger receptor class B type I (SR-BI) (Scarselli et al., 2002), claudin-1 (Evans 
et al., 2007), occludin (Ploss et al., 2009), epidermal growth factor receptor (EGFR) 
(Lupberger et al., 2011) and  Niemann-Pick C1–like 1 cholesterol absorption receptor 
(NPC1L1) (Sainz et al., 2012). The last two receptors EGFR and NPC1L1 are recently 
recognized receptors; for both of these two receptors pharmacological inhibitors already 
exist. By coordination of these host receptors, HCV enters into the host cell via clathrin 
coated endocytosis as shown in Figure 1.2 (Blanchard et al., 2006). 
 
 
 
 
Chapter 2  Review of Literature 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  12 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: HCV entry into the cell. Adapted from Moradpour et al., 2007. 
 
It is noteworthy that structural protein p7 of HCV has a very important role in 
both HCV virion assembly, release and then again in the entrance into the new cell. The 
exact mechanism of p7 role in enhancement of virion production is still a mystery. 
However, there is a supporting evidence that HCV p7 behaves like influenza A viroporin, 
M2 (Grifﬁn, 2004; Chew et al., 2009; Meshkat et al., 2009). It has a role both in virion 
secretion and entry. During the process of virion secretion, p7 proteins oligomerise and 
form ion channels over the lipid membrane of endosome. Hydrogen ions, which enter 
through the cellular ion channels, exit through the ion channels formed by p7 proteins. By 
this way, HCV glycoproteins are protected from low pH of endosome. Moreover, p7 
oligomers along with HCV-NS2 proteins have a critical role in virion assembly. When 
the virion attacks another cell through clathrin coated endocytosis, p7 proteins also have a 
role in the release of virion from endosome. By this time, p7 oligomers remain along the 
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virion and not transferred towards the lipid membrane. The pH of the endosome rises by 
the entrance of hydrogen ions through the cellular ion channels of endosome leading to 
the uncoating of core proteins from endosome. The whole phenomenon is shown in the 
Figure 1. 3 (Griffin, 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: HCV assembly/release and entry/uncoating. Adapted from Griffin, 2009. 
 
2.5.2 Translation 
 The precise mechanism of HCV translation and replication is still 
unknown. The 5' UTR plays an essential role in translation. Initially, there is produced a 
large polyprotein precursor which is processed by viral and host proteases into individual 
peptides. Among the HCV proteins, serine protease NS3 is important. It is an enzyme 
with a range of catalytic sites involving serine protease, NTPase and helicase activities. 
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All these actions take place on the surface of rough endoplasmic reticulum (RER) 
(Morikawa et al., 2011). 
2.5.3 Replication 
 NS4B acting as a cofactor of NS3 protease also has an important role in 
HCV replication. It is highly hydrophobic in nature playing its role in the assembly of 
lipid vesicles over the membranous matrix also known as membranous web. HCV NS5B 
is RdRp which forms double stranded replicative form, from a single positive stranded 
RNA. There are produced numerous positive strands RNA from a negative strand 
intermediate. HCV replication takes place on intracellular lipid membranes which 
structure is also altered by viral proteins. Particularly, the structure of ER is altered to 
membranous web. Various viral proteins are involved in the membranes alteration, but 
the most important one is NS4B, as it alone, is capable of triggering these alterations 
(Egger et al., 2002). There is also the possibility that viral replication occurs on lipid rafts 
which contain a high amount of cholesterol and sphingolipids. It has been shown that 
inhibitors of sphingolipid synthesis also inhibited HCV replication (Shi et al., 2003; 
Aizaki et al., 2004; Matto et al., 2004; Sakamoto et al., 2005). There are also a number of 
host proteins involved in the process of replication such as vesicle-associated membrane 
proteins A and B (VAP-A and VAP-B) which bind with NS5A and NS5B (Hamamoto et 
al., 2005). Similarly, Cyclophilin B possessing peptidyl-prolylcis-trans isomerase activity 
is also essential for NS5B binding with RNA (Watashi et al., 2005). 
2.5.4 Assembly 
 HCV genome is released from membranous web of ER along with NS5A 
to allow its contact with core proteins which are present on the lipid droplets (LDs). 
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There are also transferred other members of replication complex from membranous web 
to LDs, like NS3 and NS2. NS3 is responsible for the formation of a fast sedimenting 
core containing particles that are supposed to be non-infectious virions and need further 
maturation. There occur encapsidation of the viral genome by core proteins. The 
encapsidated viral genome is translocated inside the ER lumen where E1 and E2 
glycoproteins are added. NS2 protein confers infectivity to the virions by interaction of 
glycoproteins E1 and E2 with immature particles. During the maturation step, nascent 
viral particle interacts with lumen VLDLs in the form of LDs and other lipid particles 
such as Apo E  to produce LVPs (Jones and McLauchlan, 2010). The whole phenomenon 
is shown in Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Release and assembly of HCV particles. Adapted from; Jones and 
McLauchlan, 2010). 
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2.6 VIRUS-LIKE PARTICLES 
The serum of HCV infected individual contains different forms of the HCV 
particles which differ in size and density. There is little known how these different 
virions are produced. The density of these HCV particles ranges from 1.03 to 1.25 g/ml 
(Thomssen et al., 1992). Interestingly, the study on Chimpanzees demonstrated that low 
density HCV particles were more infectious than denser (Choo et al., 1989; Hijikata et 
al., 1993). Low density HCV particles contained a high amount of triglycerides, core, 
RNA, and apolipoproteins B and E (ApoB and ApoE). The major components of very 
low density lipoproteins (VLDL) and low density lipoproteins (LDL) were triglycerides, 
ApoB and ApoE. VLDL and LDL are packed in the ER of hepatocytes and secreted into 
the blood stream to be transported it to its storage site, adipocytes. It is presumed that 
HCV virions acquire triglycerides, ApoB and ApoE during assembly. HCV virions 
exploit the assembly pathway of VLDL and LDL. The transport system of VLDL and 
LDL to their storage site is interfered by HCV virions. It leads to the accumulation of 
VLDL and LDL inside the hepatocytes and ultimately to liver steatosis. HCV particles 
which do not acquire triglycerides, ApoB and ApoE are degraded, as these host 
components assist HCV from the host immune response and also increases its number of 
receptors (Andre et al., 2002; Gastaminza et al., 2008; Huang et al., 2007; Nielsen et al., 
2006; Perlemuter et al., 2002). The complete HCV life cycle is shown in Figure 1.5. 
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Figure 1.5: Life cycle of HCV. Adapted from Gastaminza et al., 2008. 
 
2.7 NATURAL HISTORY OF HCV INFECTION 
By definition, acute HCV infection must lead to chronic infection but it is 
observed that approximately 20% of individuals naturally clear the virus within initial six 
months of infection (Imran et al., 2013). The actual mechanism of spontaneous clearance 
of the virus is still unclear. There are no reliable predictors of natural clearance of viral 
infection. However, several factors are reported to be associated with spontaneous 
clearance of virus infection. The positively associated factors involved with HCV 
clearance are low age (Alter et al., 1999; Bellentani and Tiribelli et al., 2001; Micallef et 
al., 2006), female sex (Bakr et al., 2006; Micallef et al., 2006; Page et al., 2009), HCV 
non-genotype 1 (Micallef et al., 2006), Mexican Americans ethnicity (Alter, 1999) and 
SNPs of the host genome. However, study from elsewhere has sown that female sex is 
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poorly associated with the natural clearance of virus infection. Majority cases of acute 
HCV infection are without symptoms (McCaughan et al.,1992; Chung, 2005). 
Approximately, only 25% - 30% of cases are associated with symptoms within 3-12 
weeks after the infection. The main manifestation of  infection is fatigue (Alter and Seeff, 
2000; Thimme et al., 2001). 
2.8 HCV INFECTION AND LIVER FIBROSIS 
The following dynamic phases of HCV pathogenesis will help us to understand the 
natural course of virus infection. Exposure to HCV; mild HCV infection  
 natural clearance of infection within initial six months of exposure / chronicity  
  progression of liver fibrosis (compensated liver)   
 end-stage complications   cirrhosis / decompensated liver / 
hepatocellular carcinoma / liver transplantation / death  
If the individual is not successful in clearing HCV infection; then it ultimately leads to 
liver fibrosis, hepatocellular carcinoma and finally to decompensated liver. The time 
taken in the development of liver fibrosis is usually in decades. A study from the 
Japanese population has shown that it almost took 29 years to develop hepatocellular 
carcinoma after blood transfusion (Kiyosawa et al.,1990). A similar study from America 
demonstrated that it took 20.6 and 28.3 years for the development of liver cirrhosis and 
hepatocellular carcinoma respectively (Tong et al., 1995). 
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2.9 LIVER BIOPSY 
Liver biopsy is a very important marker for the determination of the stage of 
disease and the decision about the treatment options. The HCV patient at the stage of 
decompensated liver cannot be given interferon therapy as it is associated with serious 
side-effects. Two types of liver biopsies may be taken for the determination of liver 
cirrhosis. One is cross-sectional, and the other is longitudinal. On both types of biopsy 
samples, the METAVIR (Bedossa and Poynard, 1996) or Ishak (Ishak et al., 1995), 
Histological Activity Index (HAI) staging systems may be applied. Cross-sectional study 
usually involves the single liver biopsy and the date of first time blood transfusion or 
intravenous drug use. The longitudinal study of liver biopsies involves two liver biopsies 
and the rate of fibrosis development between them is assessed. In this method, there is no 
requirement of estimating the duration of disease or the assumption that the rate of 
fibrosis development is linear. There are a lot of factors which are involved in 
acceleration of liver cirrhosis e.g. male sex (Poynard et al.,1997) age (Poynard et al., 
1997), alcohol intake (Wiley et al., 1998), hepatic injury, hepatic steatosis (Adinolfi et 
al., 2001), co-infection with other viruses (Benhamou et al., 1999), viral genotype, 
ethnicity (Poynard et al., 1997), the route of blood transfusion (Roudot-Thoraval  et al., 
1997) etc. The involvements of these factors suggest that the progression of liver fibrosis 
is not linear.  
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2.10 HCV AND ESCAPE FROM THE INNATE IMMUNE SYSTEM 
2.10.1 Role of HCV Core Protein in Evasion from the Innate Immune System 
In vitro studies of cell lines suggested that core protein in a monomeric form is 
recognized by TLR2 (Barth et al., 2005). However, the recombinant or serum derived 
virus particles are not recognized by TLR2. The most probable reason for this difference, 
in recognition of monomeric core protein and core protein in intact virus might be 
attributed to changes in structural conformation. The most obvious advantage of this 
difference in recognition is to the virus. HCV escapes from the innate immune system at 
early stages at the time of its entrance into the host cell. Once, HCV persists and get hold 
of hepatocytes; it begins transcriptions and translations. At this stage, the monomeric core 
proteins that are released from hepatocytes are recognized by TLR2. Thus, this difference 
in recognition of core protein in intact and monomeric form leads to delayed activation of 
the innate immune system against the virus (Imran et al., 2012). 
2.10.2 Role of HCV NS3/4A Protease in Evasion from the Innate Immune System 
TLR3 and retinoic inducible gene 1 (RIG1) are mostly activated as the host innate 
defense mechanism against RNA viruses such as HCV (Breiman et al., 2005; Katze et 
al., 2002). The stimulation of these pathogen recognition receptors (PRRs) by double-
stranded RNA of HCV leads to signaling cascades. As a result of these two signaling 
pathways, there is an induction of nuclear factor kappa B (NF-κB), interferon regulatory 
factor 3 (IRF3) and activation protein 1 (AP1) which are the most important antiviral 
transcription factors. These transcription factors stimulate the production of type 1 and 
pro-inflammatory cytokines against HCV infection (Katze et al., 2002). Although, there 
is no direct interaction of HCV protein with TLR3 or RIG1 but its protein, NS3/4A is 
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involved in blocking the downstream elements of these signaling pathways (Imran et al., 
2012). There are two important adapter proteins, TRIF (Sharma et al., 2003) and Cardif 
(Meylan et al., 2005) in the downstream of TLR3 and RIG1 signaling pathway 
respectively. The two adapter proteins are blocked by HCV NS3/4A. By this way, HCV 
escapes from the host defense mechanisms initiated by the signaling pathways of TLR3 
and RIG1. 
2.10.3 Role of HCV NS5A Protease in Evasion from the Innate Immune System 
TLR4 recognizes HCV NS5A protein (Sene et al., 2010). However, the signaling 
cascade is also blocked by NS5A. Studies on Huh-7 cell line suggested that NS5A 
decreased the expression of TLR4. NS5A is not directly involved in reduction of TLR4 
expression; it decreases the expression of CD14 and MD-2 molecules that are involved in 
formation of TLR4 receptor complex. Moreover, cell lines studies demonstrated that the 
activity of MyD88 is also inhibited by NS5A attachment. MyD88 is an important adapter 
protein of TLR4 signaling pathway (Tamura et al., 2011). NS5A also stimulates the 
induction of anti-inflammatory cytokines such as IL10, TGFβ, IL6 which in turn leads to 
down-regulation of proinflammatory cytokine such as IL12 (Ma et al., 2001). 
2.11 HCV AND ESCAPE FROM THE ADAPTIVE IMMUNE 
SYSTEM 
2.11.1 Role of HCV Core Protein in Evasion from the Adaptive Immune System 
Co-culturing of monocytes and T-cells from HCV infected patients along with 
HCV core protein results in the production of APCs with a limited ability to drive Th-17 
differentiation as compared to healthy controls. Further research showed that the 
defective Th-17 differentiation is due to impaired production of IL17 by these cells 
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(Triantaflou et al., 2006; Watanabe et al., 2006; McGeachy and Cua, 2008). The 
impaired IL17 induction is attributed to impaired IL6 production by antigen presenting 
cells (APCs). Thus, core protein stimulates TLR2 that results in the production of a series 
of cytokines; among these cytokines, IL6 is important as its production is impaired. 
Decreased IL6 induction by APCs leads to impaired stimulation of IL17 which in turn 
results in defective Th-17 differentiation. By this way, HCV exploits the host adaptive 
immune system of Th-17 cells (Dolganiuc et al., 2004). 
During the initial step of virus entry into the host cell, there is no activation of 
TLR2 signaling pathway as the intact core protein cannot activates TLR2. However, core 
protein is able to induce TLR9 signaling pathway. There is a production of IFN-α via 
TLR9 signaling pathway. IFN- α is an antiviral cytokine. It inhibits HCV replication but, 
once the virus is persisted somehow, then there is also production of monomeric core 
proteins of HCV. The HCV monomeric core protein leads to the production of IL10 and 
TNF-α by stimulating TLR2 signaling pathway. IL10 and TNF-α exert an inhibitory 
effects on TLR9-induced IFN-α production. Moreover, rIL10 and TNF-α suppress 
apoptosis of plasmacytoid cell (PDC) in a dose dependent manner. Apoptosis of the 
infected cell is a host defense mechanism against the spread of infection. In conclusion, 
HCV help itself against IFN-α by the production of IL10 and TNF-α and also maintains 
its persistence in the PDC by inhibiting PDC apoptosis (Payvandi et al., 1998; Rissoan et 
al., 1999; Gary et al., 2002; Duramad et al., 2003). 
2.11.2 Role of HCV NS3/4A protease in Evasion from the Adaptive Immune System 
NS3/4A also plays an important role in evasion from the adaptive immune 
system. It abrogates TLR3 and RIG1 signaling pathways by inhibiting the two important 
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adapter proteins of these signaling pathways, TRIF and Cardif. These two pathways are 
essential for the activation of NF-κB and IRF3, which in turns leads to the failure in 
induction of IFN-α and IFN-β. Moreover, NS3/4A suppresses or delay the CD8 T cell 
responses which are essential for the elimination of virus (Iwasaki and Medzhitov, 2004; 
Hoebe and Beutler, 2004). 
2.11.3 Role of HCV NS5A in Evasion from the Adaptive Immune System  
NS5A is a ligand of TLR4 (Sene et al., 2010). It stimulates the production of IL10 
and TGFβ via TLR4 signaling pathway. Blocking of IL10 or its receptors result in 
decreased production of TGFβ by NS5A in a dose dependent manner. Thus, TGFβ 
production is mainly dependent on autocrine activity of IL10. IL10 is produced by P38 
and P13K pathway (Ma et al., 2001). P13K is an endogenous suppressor of IL12, which 
is a pro-inflammatory cytokine and support HCV persistence (Fukao et al., 2002). 
NKG2D  is pathogen recognition receptors that are mainly expressed on natural 
killer (NK) cells and CD8 T cells (Bauer et al., 1999). These receptors are important 
component of the host immune system as viruses, bacteria and other pathogens have 
developed different strategies to evade this host defense mechanism. On the normal cells, 
NKG2D are not expressed (Groh et al., 2002). These are expressed as a result of some 
stress such as DNA damage or an invasion by some pathogen. TGFβ, which is produced 
by the activation of TLR4 signaling pathway via HCV NS5A, causes the down-regulation 
of these receptors. The down-regulation of NKG2D receptors on NK cells and CD8 T 
cells has functional consequences. It causes impaired production of IFNγ and CD107a 
degranulation by NK cells (Sene et al., 2010). The exact role of NKG2D in HCV 
infection is still to be cleared (Oliviero et al., 2009; De Maria et al., 2007). 
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2.12 STANDARD TREATMENT OF HCV INFECTION 
Interferon monotherapy was used for HCV infection even before the discovery of 
the virus. The success rate was only 6% - 10% (Davis et al., 1989; Di Bisceglie et al., 
1989). The successful treatment against HCV is defined as sustained virological response 
(SVR), avirimia for six months after the completion of treatment. The continuous 
struggle for improving the response rate led to the discovery of broad-spectrum antiviral 
agent, ribavirin. Ribavirin is a guanosine nucleotide analogue. The addition of ribavirin 
leads to the improvement in success rate up to more than 30% (McHutchison et al., 1998; 
Poynard et al., 1998). The success rate was further improved by the addition of pegylated 
interferon instead of simple interferon. Pegylated interferon increases the half-life of 
interferon as polyethylene is covalently attached with interferon. The success rate was 
attained up to 50% (Manns et al., 2001; Fried et al, 2002; Hadziyannis et al., 2004).  
Currently, there is another addition to combinational therapy of HCV infection, Ribvirin 
or Telaprevir.  The triple therapy (pegylated interferon, ribavirin and protease inhibitor) is 
considered as a standard of care against HCV genotype 1 (Imran et al., 2013b). 
More than two decades have passed since the discovery of interferon and ribavirin 
as a treatment of HCV infection; their exact mechanisms of action are still unknown. 
Interferon is considered not to directly act on the virus; it binds to the host cell receptors 
and stimulates the induction of interferon stimulated genes (ISGs). There are more than 
300 ISGs which confers antiviral activity (Feld and Hoofnagle, 2005). ISGs most 
probably block HCV replication. HCV escapes the action of ISGs by interfering the 
transcription of these genes by its core protein (De Lucas and Bartolome, 2005; Choi and 
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Ou, 2006a). Moreover, HCV NS3/4A protease also inhibits interferon amplification loop 
(De Lucas and Bartolome, 2005; Karayiannis, 2005; Choi and Ou, 2006b). 
Ribavirin alone has no appreciable effect on HCV infection (Bodenheimer et al., 
1997), but its combination with interferon accelerates the response rate. The most 
probable reason for this augmented immune response is attributed to down-regulated 
effect on inhibitory pathways of interferon. It also inhibits host inosine monophosphate 
dehydrogenase (IMDH) enzyme that result in depletion of GTP pool, essentially required 
for the viral RNA synthesis (Lau et al., 2002). Additionally, ribavirin has a direct effect 
on HCV RdRp by binding its nucleoside binding region and inducing mutations in viral 
RNA synthesis. All these functions of ribavirin were concluded from in-vitro studies. It is 
still unclear that any or all of these functions of ribavirin will exist in in-vivo also (Feld 
and Hoofnagle, 2005). 
2.12.1 Side-effects of Interferon Based Therapy 
Although interferon based therapy of HCV is a gold standard treatment of HCV 
infection as it is successful in more than half number of patients but 10% - 20% of 
patients have to stop the treatment due to a lot of serious side-effects (Manns et al., 
2006). Major side effects of interferon based therapy are fever, fatigue and headache 
(Hadziyannis et al., 2004). The most severe side effect of interferon based therapy is 
depression which is most likely due to effect of interferon on serotonin activity. 
Moreover, dose dependent haemolyticanaemia is also caused by ribavirin that leads to the 
discontinuation of treatment in 32% - 42 % of cases (Fried et al, 2002). 
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2.13 FUTURE THERAPIES OF HCV INFECTION 
HCV comprises four structural proteins and six non-structural proteins. There is 
the development of anti-viral drugs against each viral protein as shown in table 1.1 
(Imran et al., 2013b). NS3/4A protease inhibitors and nucleoside / nucleotide inhibitors 
against are currently in the most advanced stages of clinical developments. 
Table 1.1: Future drugs against hepatitis C virus infection. 
Company Drug Mechanism of 
action 
Stage of clinical 
development 
Biotron Limited BIT225 Inhibit HCV P7 
protein 
Completed phase 
IIa 
Roche Danoprevir Inhibit NS3 protein Phase II 
Merck & Co., Vaniprevir Inhibit NS3 protein Phase II 
Merck Boceprevir Inhibit NS3 protein APPROVED 
Vertex Telaprevir Inhibit NS3 protein APPROVED 
Tibotec/Janssen TMC-435 Inhibit NS3 protein Phase III 
BoehringerIngelheim  
 
 
BI 201335 Inhibit NS3 protein Phase III 
Gilead and Achillion 
Pharmaceuticals 
ACH-806 
 
NS4A antagonist Phase 1b/2 
Eiger 
BioPharmaceuticals 
Clemizole 
hydrochloride 
Inhibitor of 
NS4B:RNA 
Phase 1b 
Med Chem express  Anguizole inhibitor of HCV 
RNA replication 
Phase 1b 
Bristol Myer Squibb BMS-790052 NS5A inhibitor Phase III 
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Bristol Myer Squibb BMS 824 NS5A inhibitor Phase II 
Gilead Sciences Inc GS-5885 NS5A inhibitor Phase II 
GlaxoSmithKline GSK2336805 NS5A inhibitor Phase II 
Presidio 
Pharmaceuticals 
PPI-668 NS5A inhibitor Phase II 
Pharmasset PSI-7851 NS5B inhibitor Phase II 
Abbott ABT-072 Non-Nucleoside 
Polymerase 
Inhibitor 
Phase II 
 
Abbott ABT-333 Non-Nucleoside 
Polymerase 
Inhibitor 
Phase  III 
SantarisPharma SPC3649 Lock Nucleic Acid 
mRNA122 inhibitor 
Phase 1 
Human Genome 
Sciences 
Zalbin Immunomodulator Phase  III 
Novartis / 
Debiopharm 
Debio 025 Cyclophilin 
Inhibitor 
Phase  III 
SciClonePharma / 
Sigmatau 
Zadaxin - 
thymalfasin 
Immunomodulator Phase  III 
 
Recently two protease inhibitors, Boceprevir or Telaprevir are approved as a part of 
combinational therapy against HCV genotype 1. 
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2.13.1 Boceprevir 
Boceprevir is a ketoamide inhibitor of HCV NS3 protease. It forms a reversible 
covalent bond with NS3 and blocks its protease activity (Mederacke et al., 2009; Sarrazin 
and Zeuzem, 2010). Boceprevir monotherapy against HCV infection is not effective due 
to the development of viral resistance within a week of therapy. Hence, it is highly 
recommended that four tablets of Boceprevir, each 200 mg should be given to the 
patients after 7-9 hours with the optimal dose of peg-interferon plus ribavirin (Malcolm et 
al., 2006). The published data have shown that the response rate to interferon based 
therapy is different in black and non-black African-American patients; therefore the 
response rate of triple therapy was studied in two different cohorts. The improved SVR 
rate to triple therapy of black African-American cohort was 19% - 30%, while for non-
black African-American cohort, it was 27% - 28%. The triple therapy against HCV 
genotype 1 is equally efficient; whether it is used with IFNα 2a or IFNα 2b as a part of 
standard treatment (Poordad et al., 2011). 
2.13.2 Telaprevir 
Telaprevir also known as VX-950 is a linear peptidomimetic inhibitor possessing 
a ketoamide serine trap warhead for HCV NS3/4A. Its monotherapy against HCV 
infection is also not recommended due to the immediate emergence of viral resistance. 
Two tablets of Telaprevir are recommended, each 375 mg after every 7-9 hour along with 
the optimal dose of peg-interferon plus ribavirin. Telaprevir was given for 12 weeks in 
phase III stage of clinical development due to the development of severe side-effects 
(McHutchison et al., 2010). Two large studies of treatment naive patients showed that 
triple therapy was more effective than double therapy. However, triple therapy is mostly 
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dependent on HCV genotype. The best results are shown by HCV genotype 1 as 
compared to HCV genotype 2 and 3 (Jacobson et al., 2011; Chatel-Chaix et al., 2010). 
Retreatment of the relapse patients by double therapy showed SVR rate of 24% - 34%, 
while by triple therapy it was 69% - 80%. Hence, relapse patients are more suitable for 
treatment with triple therapy. 
In conclusion, different therapies are developing against HCV infection but not a 
single therapy can completely eradicate HCV infection. Interferon is still used as a part of 
combinational therapy. The addition of direct acting antiviral agent to interferon therapy 
also causes the addition of new side-effects that were not previously reported with 
interferon plus ribavirin treatment. The future therapy of HCV infection is expected to be 
the combination of only direct acting antiviral agents without the involvement of 
interferon and ribavirin to get rid-off its side-effects during the course of therapy (Imran 
et al., 2013b). 
2.14 ROLE OF VIRAL FACTORS IN INTERFERON BASED 
THERAPY 
There are multiple viral factors which also have an important role in the interferon 
based therapy of HCV infection. The low viral titer before the treatment is the predictor 
of SVR. HCV genotype is also an important marker of treatment response. The treatment 
is easy for HCV genotype 3 as compared to other genotypes. However, no patient should 
be left without treatment purely on the basis of HCV genotype as its predictive value is 
55%. (Yuen and Lai, 2006). Genetic variations in domain III portion of 5′ UTR were 
observed more commonly in SVR patients as compared to breakthrough patients. These 
mutations were insertion mutations and induced altered Watson-Crick base pairing that 
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led to decreased RNA stability and binding affinity with ribosomes. Thus, genetic 
variations of 5′ UTR domain III are positively associated with interferon based therapy of 
HCV infection (El Awadyet al., 2009). Genetic variations of HCV core, p7, NS2, NS3, 
NS5 are also noteworthy. These genetic variations were not specific for their positions in 
viral proteins. The random genetic mutations in viral sequences were more common in 
SVR patients as compared to NR patients. A mutation in HCV core protein at residue 71 
was found to be a significant predictor of treatment response in triple therapy of HCV 
infection (Akuta et al., 2010). How these genetic variations of virus play roles in 
treatment response is still to be discovered. 
2.15 ROLE OF HOST FACTORS IN INTERFERON BASED 
THERAPY 
2.15.1 Age 
Age is defined as a decline in body functions and the immune system. Elderly 
people are comparatively more at risk for invasion by pathogens (Aspinall et al., 2007). 
The immune system of aged people for spontaneous clearance of pathogens or response 
to treatment is also weak due to decreased number of CD4 and CD8 T cells, naive T 
cells, B cells. There is also a shift from Th1 to Th2 cytokines production and expression 
of PRRs. All these changes are associated with failure in clearance of pathogen and 
treatment outcomes (Ginaldi et al., 2001). Phase III studies (NV15801/NV15942) of 569 
HCV genotype 1 patients treated with peg-interferon and ribavirin demonstrated that the 
treatment response rate in young patients was higher as compared to aged patients. 
Moreover, the relapse rate was also higher in elderly patients than younger patients (Dey 
and Chaudhury, 1997). 
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2.15.2 Sex 
Formally, it was considered that female sex favors response to interferon based 
therapy (Poynard et al., 1998) but later on large respective studies concluded that there is 
no effect of gender on interferon based therapy of HCV infection (Manns and 
McHutchison, 2001). 
2.15.3 Insulin Resistance 
Insulin resistance (IR) is a condition where high concentration of insulin is 
required to maintain normal glycemia and appropriate consumption of glucose. Both 
genetic factors and environmental factors may contribute in the development of IR. The 
genetic factors may generate abnormalities either in insulin gene or its receptors and 
members of the signaling pathway. The environmental factors may involve various 
pathogens. IR is often associated with HCV infection (Zein et al., 2005). The risk of 
developing type 2 diabetes (T2D) increases 11 times when the patient is infected by HCV 
(Harrison, 2006). Moreover, it was found that HCV infection and IR led to the 
development of extra-hepatic manifestations and a decreased response rate to interferon 
therapy. IR may also be induced by HCV core protein. HCV core protein plays its role by 
proteosomal degradation of insulin receptor substrate 1 and 2 and blocks intracellular 
insulin signaling pathway. On the other side, interferon therapy of HCV infection is also 
influenced by IR. IR leads to upregulation of SOCS3 cytokines, which interfere with 
interferon signaling pathways (Walsh et al., 2006). Thus, HCV may not only induces IR 
but may further exploits this weakness for its defense against interferon action. 
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2.15.4 Race 
Racial differences also influence the rate of SVR against HCV infection (Reddy et 
al., 1999). Peg-interferon plus ribavirin treatment of African-American and Caucasian-
American demonstrated that the success rate of therapy was 28% and 52% respectively 
(Conjeevaram et al., 2006). Moreover, the viral breakthroughs were also more frequent 
among the African-American as compared to Caucasian-American (Conjeevaram et al., 
2006). The mechanisms behind these observed differences are poorly understood and 
may be attributed to multiple factors. Some factors among them are high obesity rate and 
prevalence of HCV genotype 1 among African-American (McHutchison et al., 2000). 
Furthermore, the distribution of treatment responsive SNP, IL28B rs12979860 was less 
prevalent among African-American than Caucasian-Americans. The distribution of this 
particular SNP among the African-American was 16% with a treatment success rate of 47 
%, while among the Caucasian-Americans, it was 39% with a treatment success rate of 
81% (Clark et al., 2010). 
2.15.5 Obesity 
 Individuals with body mass index (BMI) ≥ 30 kg/m2 are defined as obese. It is 
estimated that 30% HCV infected patients are obese (Bressler et al.,  2003; Hickman et 
al., 2003). Obesity is linked with a lower treatment response to interferon based therapy 
of HCV infection (Camma et al., 2004). There are proposed different mechanisms to 
explain how obesity decreases the response rate to interferon based therapy of HCV 
infection. The first mechanism suggested that obesity is an inflammatory condition 
resulting in abnormal response to interferon based therapy of HCV infection. The second 
mechanism highlighted that obesity has a role in the development of liver steatosis, 
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fibrosis, cirrhosis and hepatocellular carcinoma that leads to poor response to interferon 
therapy. According to third mechanism the bioavailability of peg-interferon is decreased 
by obesity (Charlton et al., 2006). A recent large study concluded that there is no 
significant effect of BMI on the treatment outcomes of HCV infection. However, it is 
established that weight loss plays an important in the treatment outcomes of HCV 
infection as it causes down regulation of liver enzymes and fibrosis development 
(Hickman et al., 2002). 
2.15.6 Hepatic steatosis 
 Disease progression in HCV infection is also accelerated by hepatic steatosis 
(Commentary et al., 2001). In case of HCV genotype 3, the virus itself is the major cause 
for inducing hepatic steatosis while in case of other HCV genotypes obesity and central 
adiposity are the key factors that are involved in the induction of hepatic steatosis 
(Khattab et al., 2010). 
2.15.7 Alcohol 
 Alcohol intake is also responsible for the poor treatment response to interferon 
based therapy of HCV infection. Alcohol causes histological activity and liver fibrosis. In 
chronic HCV infection, even the moderate intake of alcohol leads to the progression of 
disease and a poor treatment response (Poynard et al., 1997; Singal and Anand, 2007). 
2.16 SINGLE NUCLEOTIDE POLYMORPHISMS  
 There are many genetic variations in the human genome. Most of these genetic 
variations are not important to us, but some genetic variations are medically relevant. The 
presence of some genetic variations may predispose us to infectious disease or may 
weaken the immune system for disease. In some more extreme situation mere the 
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presence or absence of a genetic variation in the genome may be the cause of a life 
threatening disease e.g. sickle cell anemia. Most of these genetic variations come in the 
form of SNPs. SNPs are haphazardly distributed in our genome and make each individual 
unique (Brookes, 1999). Approximately, 99.9% of an individual genome is matched with 
the genome of other individuals in a community. In each individual genome, one base 
pair (bp) after every 500 – 1000 bp differs from the one which is the most prevalent in the 
population. It is supposed that three to six million small genetic variations are present in 
our genome. When such variations are present only in 1% of the population, they are 
referred as SNPs (Stoneking, 2001). 
2.17 SNPS AND THE TREATMENT RESPONSE 
 SNPs may modify the body response to drug actions by the following three ways. 
Firstly, SNPs may play their role by abnormal absorption of drugs. Secondly, some drugs 
require to be further processed in the body. Genetic variations of the body may interfere 
with the internal processing of the drug. Thirdly, after taking the drug, it uses the body 
transport system to deliver to its site of action. The body mostly uses proteins as a 
transport system. A genetic variation of the transport protein or some other protein that 
interferes the transport system may leads to the inappropriate concentration of the drug to 
its site of action (Chakravarti, 2001). 
 In-conclusion, disease relevant SNPs may provide us a molecular basis of the 
disease and its treatment outcomes. SNPs may play a significant role in a personalized 
treatment. For pharmaceutical industries also, SNPs are of prime importance in drugs 
research and development (Weiner and Hudson, 2002). 
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2.18 HOST SNPs AND HCV INFECTION 
 HCV infection is one of the most important examples where genetic information 
is utilized for the treatment of infection. Recently, genetic testing of IL28B is 
recommended by FDA before interferon based therapy of HCV genotype 1 infection. 
Currently candidate gene approaches are in use for the treatment of HCV infection 
(Mosbruger et al.,2010). Table 2.2 shows those SNPs in the host genome that play critical 
roles in progression of HCV infection or treatment outcomes. SNPs, which are 
highlighted blue boldtyped, are discussed in detail as these polymorphisms were also 
selected in the current study. 
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Table 2.2: Association of host SNPs with treatment response to HCV infection 
Gene symbol Function SNP Effect on interferon 
therapy 
IFN –λ 
IL29 (IFN-λ1)  rs8099917 TT genotype is 
favorable 
IL28A (IFN-λ2) Inhibit viral 
replication 
rs12980275 AA genotype is 
favorable 
IL28B (IFN-λ3)  rs12979860 CC genotype is 
favorable 
IFN - γ 
 
Inhibit viral 
replication 
-768G Enhances promoter 
activity 2-3 folds 
MBL Pathogen 
recognition receptor 
O/A at exon 1 
At promoter region: 
MBL2*H,Land 
X,Y. 
X or O mutations 
linked with non-
responsiveness 
CTLA4 Down regulates  T 
cell functions 
-318 C/T 
49 G/A 
 
-318C, 49G are 
favorably linked with 
therapy response. 
IL10 Anti-inflammatory, 
Down regulates 
MHC1and MHC II 
molecules 
−1082, 
−819, 
−592 
 
−819T and −592A are 
positively associated 
IL18 
 
Pro-inflammatory 
cytokine 
Induces IFN-γ 
-607 C/A, 
-137 G/C 
 
-607A and -137C  are 
positively associated 
TRAIL Induces apoptosis in 
virally infected cells 
rs4242392 Poorly associated 
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TGFβ1 Multifunctional 
cytokine 
codon 10T/C , 
codon 25G/C 
Positively associated 
Mx1 
 
Antiviral activities G/T at nt -88 Positively associated 
Osteopontin Induces Th1 
response 
nt 442, 
nt 1748 
T/T at nt -442 
G/G or G/A at 1748 
Positively associated 
with SVR 
 
LMP7 
 
HLA-1 antigen 
presentation 
 
 
LMP7-K 
 
Positively associated 
with SVR 
OAS1 converts ATP into 
2'-5' linked 
oligomers of 
adenosine 
at exon 7 SAS AA genotype is 
poorly associated 
 
 
2.18.1 IL28B and HCV Infection 
Interferon-λ was first reported in 2003. The three members of the family of 
interferon λ are IFN λ1, 2, and 3 are also recognized as IL29, IL28A and IL28B 
respectively. The three members show approximately 80% homology with each other. 
Although, IFN-λ homology with IL10 and IFN-α is minimal but like IL10, IFN-λ also 
encompasses 5 - 6 exons (Gad et al., 2009; Hwang et al., 2006; Sheppard et al., 2003). 
Most of the immune cells, alveolar epithelial cells, hepatocytes, cell lines and neuronal 
cells produce IFN-λ, but the major source of its production are dendritic cells DCs (Ank 
et al., 2008; Coccia et al., 2004; Iversen et al., 2010; Sommereyns et al., 2008; Wang et 
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al., 2009). Like all other interferons, IFN-λ is also mainly produced against viruses. IFN-
λ is mainly produced by stimulation of TLR signaling pathways (Marcello et al., 2006). 
The production of IFN-λ is reported against a series of viruses such as influenza virus A, 
HBV, HIV, dengue virus, cytomegalovirus, herpes simplex virus 1, 
Encephalomyocarditis virus (EMCV), and HCV (Hou et al., 2009; Hwang and Chen, 
2006; Marcello et al., 2006; Sheppard et al., 2003). It was shown that IFN-λ not only 
inhibits viral replication but also possessed immune-modulatory functions. It plays an 
important role in the differentiation and maturation of the immune cells (Megjugorac et 
al., 2009; Mennech and Uze, 2006; Wolk et al., 2008). Thus, IFN-λ also plays its part in 
the modulation of the adaptive immune system against viruses. 
In 2002, there was the development of the human HapMap project which greatly 
facilitates genome wide association studies (GWAS) of various infectious diseases. This 
technique differs from the candidate gene approach in which the distribution of pre-
identified relevant gene in the population is studied. The first study of GWAS for HCV 
infection involved 1651 HCV patients from mixed ethnicity (American European, 
Hispanic and African) (Ge et al., 2009). These patients received the peg-interferon α plus 
ribavirin treatment for HCV infection. An astonishing association was found between the 
treatment outcomes and a cluster of seven SNPs in the vicinity of IL28B gene. The most 
important of these SNPs was rs12979860. It demonstrated a significant value; P = 1. 
063×10
25
. The GWAS study showed that not a single SNP of some other gene was 
associated with the treatment outcomes of HCV infection. The SVR rate among the 
patients was 78%, 38% and 28% for IL28B rs12979860 genotypes, C/C, T/C and T/T 
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respectively. Thus, the protective allele against HCV infection at IL28B rs12979860 was 
C irrespective of ethnicity.  
The results of many other studies from Australian, Hispanic, European, African 
and Japanese population also confirmed the conclusions of Ge et al., (2009) studies 
(Labie and Gilgenkrantz, 2010; Mangia et al., 2010; McCarthy et al., 2010; Montes-Cano 
et al., 2010; Mosbruger et al., 2010, Rallon et al., 2010; Thomas et al., 2009). Soon after 
the landmark discovery of Ge et al., (2009) candidate gene approach for IL28B genetic 
testing demonstrated that IL28B rs12979860 also possessed a role in the spontaneous 
clearance of HCV infection in African and Caucasian population. The results showed that 
individuals possessing the risk allele are three times less likely to spontaneously clear 
HCV infection than individual possessing favorable allele. These results were further 
strengthened by another large GWAS study (Rauch et al., 2010). 
Regarding IL28B rs12979860, it is clear that the response rate to interferon based 
therapy of HCV infection is not dependent on ethnicity, but its dependence or 
independence on HCV genotype is still unclear. The reported data suggest that there is an 
association between IL28B rs12979860 polymorphism with interferon based therapy in 
HCV genotype 1 but not in HCV genotype 2 and 3 (Novick et al., 1994; Stark et al., 
1998). However, two other studies noted the association of IL28B rs12979860 
polymorphism with HCV genotype 2 and 3 (De Veer et al., 2001; Darnell, 1997). 
Interestingly, one study indicated that the treatment predictive capability of IL28B 
rs12979860 polymorphism for genotype 3 was even greater than genotype 1 (0.0007) 
(Darnell, 1997). 
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The other two important SNPs of IL28B, rs12980275, and rs8099917 showed an 
association of treatment outcomes of HCV infection with ethnicity (Doyle et al., 2006; 
Lange and Zeuzem, 2011). Interferon-λ based HCV drugs are possible candidates for 
treating HCV infection. These drugs have relatively fewer side-effects than IFN-α and β 
base drugs as there are a comparatively less number of IFN-λ receptors, permitting more 
targeted therapy (Imran et al., 2013a). 
The most important query about IL28 SNPs is that whether these SNPs have any 
effect on IFN-λ production. Two studies on peripheral blood mononuclear cells (PBMCs) 
proposed that the protective allele is related with up-regulation of IFN-λ3 in PBMCs (Soh 
et al.,1994; Kotenko et al., 2003). The results were not replicated by other group (Pestka 
et al., 2004). However, one consistent finding of all the studies was the high viral titer in 
patients with protective allele than those patients possessing risk allele (Darnell, 1997). It 
seems to be irrational as pre-treatment high viral load is associated with poor response to 
interferon therapy. The most possible reason may be no effect of protective or risk allele 
on viral load (Marcello et al., 2006). 
In-conclusion, the future therapies of HCV infection would be the competition 
between peg-interferon α and peg-interferon λ1. Moreover, the presence of the risk allele 
of IFNλ3 may lead us towards alternative treatment options. HCV provides us the 
opportunity to step forward for personalized treatment options. Thus, only those patients 
may take the treatments that are likely to benefit from it. The most important point is to 
solve the puzzle, how IFNλ3 polymorphism affects acute HCV infection and the 
treatment response. Furthermore, it is still a challenge to search how these 
polymorphisms influence IFNλ3 structure. Unlocking the immune-modulatory functions 
Chapter 2  Review of Literature 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  41 
 
of IFNλ3 will help us to understand its antiviral mechanisms and toxicities. Overall, the 
link between treatment outcomes of HCV infection and IFNλ SNPs is a major step and 
raises new questions to be solved (Kelly et al., 2011). 
2.18.2 TGFβ and HCV Infection 
TGFβ is secreted by most of the cells. The major sources of TGFβ secretion are 
macrophages. It is secreted in the latent form, complexed with two polypeptides. The 
active TGFβ is produced by the action of serum proteinases such as plasmin (Kitamura et 
al., 1997). TGFβ is secreted in three different isoforms TGFβ1, TGFβ2, TGFβ3. TGFβ is 
a chemo-attractant cytokine with multiple functions. The main function is its role in 
cellular differentiation, apoptosis, degradation and production of extra-cellular matrix 
(Massague et al., 1998; Derynck et al., 2001). 
TGFβ receptor comprises of two transmembrane units, TβR1 and TβR II. The 
ligand binding leads to TβR II activation which phosphorylates TβR1. TβR1 
phosphorylates the receptor specific R-Smad and common receptor Co-Smad. The 
cmplexes of R-Smad and Co-Smad are translocated to the nucleus and induces 
transcription and apoptosis (Schuster and Krieglstein, 2002). HCV NS5A protein was 
shown to block TGFβ signaling pathway via binding TβR1. There is a direct interaction 
between NS5A protein and TβR1 leading to inhibition of R-Smad complexes and their 
translocation to the nucleus. Blocking of TGFβ signaling pathway also invites infection 
by other viruses such as HBV, adenovirus and human papiloma virus as the proteins of 
these viruses also inhibit the members of the TGFβ signaling cascade (Choi, 2006). 
Dysregulation of TGFβ cytokines were associated with the progression of liver 
fibrosis and persistence of HCV infection (Okumoto et al., 2004). TGFβ is a well known 
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suppressor of NK cells that are the major sources of IFN-γ and IL12 production. It also 
inhibits the cytotoxicity and proliferation of NK cells. Over-suppression of NK cells may 
leads to HCV persistence (Rook et al., 1986). TGFβ1 SNP, -509T was associated with 
higher plasma level of TGFβ (Grainger et al., 1999). Moreover, -509CC genotype and 
"C" allele was found to be associated with the natural clearance of HCV infection. TGFβ 
-509CC genotype is responsible for a low secretion of TGFβ, which in turn leads to a 
weak suppression of NK cells and better immune response against HCV infection. 
Furthermore, it is reported that TGFβ down-regulates the expression of NKG2D on NK 
cells at the transcriptional level. Blocking the activity of TGFβ by RNA interference 
leads to increased activity of NK cells (Castriconi et al., 2003; Taniguchi et al., 2004).  It 
is still unknown that whether TGFβ polymorphisms at promoter level that regulates its 
secretion causes different activity of NK cells or IFN-γ and IL12 secretion (Kimura et al., 
2006). 
HCV core protein is reported to up-regulate TGFβ secretion (Taniguchi et al., 
2004), leading to enhanced liver fibrosis and the development of hepatocellular 
carcinoma (Kimura et al., 2006). TGFβ polymorphism at codon 10 position is considered 
to influence its export efficacy (Grainger et al., 1999). Moreover, the functional 
polymorphism of TGFβ at codon 25 is associated with graft rejection after liver 
transplantation in chronic HCV patients (Eurich et al., 2011). 
2.18.3 Oligoadenylatesynthetase Gene and HCV Infection 
Oligoadenylatesynthetase (OAS) is an enzyme that is induced by interferon 
stimulation and double stranded RNA. It uses adenosine triphosphate (ATP) to produce 
2', 5'-oligoadenylates (2-5As). 2-5As binds and stimulates RNaseL system which in turns 
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leads to the degradation of double stranded RNA and blocks the synthesis of viral 
protein. Hence, this protein possesses a significant antiviral activity (Hamano et al., 2005; 
Xiang et al., 2003). Recent study has proved that genetic variations of OAS1 gene were 
associated with asymptomatic west nile virus (WNV) infection and disease progression 
(Bigham et al., 2011). Additionally, associations between OAS1 SNPs and diabetes 
mellitus 1 (Fedetz et al., 2006), multiple sclerosis and (Cagliani et al., 2012) prostate 
cancer (Mandal et al., 2011) are also reported.  
The gene family of 2′–5′ OAS involves three members, OAS1, OAS2 and OAS3. 
Regarding HCV infection, OAS1 is of special importance. It is positioned on 
chromosome 12q24.2, and released in four different isoforms; p42, p44, p46 and p48 
(Nguyen and Keeffe, 2005). The published data has suggested a significant role of OAS-
RNaseL system in natural clearance of viral infections (Mashimo et al., 2002; Perelygin 
et al., 2002; Lucas and Mashimo, 2003). Cell line studies of HCV infection demonstrated 
that HCV core protein activates OAS1 gene promoter. Further research in the same 
direction revealed that interferon based therapy of cell lines enhanced HCV core activity 
to induce OAS1 gene (Naganuma et al., 2000). It was concluded from these studies that 
any genetic variation of OAS gene may be important determinant in the treatment 
outcomes of virus infection. Search for SNPs in OAS1 gene exposed 36 SNPs. There was 
found one SNP at 5' UTR, three in promoter, eight in exon and twenty four in introns. 
Twelve of these genetic markers were associated with the enzymatic activity of OAS1 
gene. Although, it is an important component of the host immune system against virus 
infections but its sequence is not strictly conserved. The strongest genetic association 
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between OAS1 gene and virus infection was found at exon 7 splice accepter site (El 
Awady et al., 2009). 
2.18.4 IL18 and HCV Infection 
Interleukin-18 (IL18) is an important member of IL1 family. Unlike IL1, IL18 is a 
pivotal mediator of Th1 cytokines (Dinarello,1996; Dinarello et al., 1998; Okamura et 
al., 1995). However, the common function between the two cytokines is the induction of 
pro-inflammatory cytokines (Puren et al., 1998). IL18 plays an important role in both the 
innate and adaptive immune system. IL18 was first discovered in 1989 as IFN-γ inducing 
factor (Nakamura et al., 1989). IL18 induces the production of IFN-γ mainly from NK 
cells (Tsutsui et al., 1996)  and T cells (Okamura et al., 1995). IL18 is produced by a 
number of cells such as dendritic cells, osteoblasts, T-cells, B-cells, corneal epithelial 
cells, and glucocorticoid-secreting adrenal cortex cells, but the major sources of its 
production are macrophages (Dinarello, 2000). IL18, like IL1β is produced in the 
precursor form which is cleaved by caspase 1 to produce active mature IL18. IL18 is 
mainly produced in response to LPS and other microbe antigens stimulation along with 
IL12 to promote inflammatory response. In vitro studies also demonstrated that IL18 may 
promote Th2 response in the absence of IL12 (Nakanishi et al., 2001). The bioactivities 
of IL18 are regulated by IL18 binding protein a (IL18BPa). The bioactivity of IL18 is 
mainly associated with inflammatory diseases such as septic shock, colitis, crohn’s 
disease, rheumatoid arthritis, atherosclerosis, myasthenia gravis and multiple sclerosis. 
Antitumor activities are also suggested for IL18 (Micallef et al., 1997). 
In HCV infection, IL18 is mainly regulated by TNFα. TNFα regulates the 
production of IL18BP that in turn leads to the modulation of IL18 and fibrosis 
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progression (Zecchina et al., 2001). In chronic HCV infection, the level of IL18 and its 
receptors was raised and linked with the poor treatment outcomes (Asakawa et al., 2006). 
Interferon therapy of  HCV infection increased the level of IL18BP, 3-24 folds (Kaser et 
al., 2002). Two important genetic variations are reported in the promoter region of IL18; 
IL18 -607 and IL18 -137. The minor alleles (-607A and -137C) were linked with lower 
promoter activity while the major alleles (-607C and -137G) were linked with higher 
promoter activity. The association of these two polymorphisms of IL18 with some other 
diseases such as cardiovascular diseases (Tiret et al., 2005) crohns disease (Glas et al., 
2005) human immunodeﬁciency virus (HIV) infection (Segat et al., 2006), HBV (Zhou et 
al., 2013; Kimura, 2002) and HCV (Manohar et al., 2009) are also reported. 
2.18.5 Osteopontin and HCV Infection 
Osteopontin (OPN) is a phosphoprotein secreted by the most tissues and cells. It 
has a high degree of posttranslational modification that can also differ from cell to cell. 
As OPN is involved in most of the body immune system, it was discovered in many 
laboratories with different names. The protein was discovered for the first time in 1979 as 
a transformation associated protein (Senger et al., 1979) and later on it was named as 
secreted phosphoprotein 1 (SPP1). OPN was also defined as an early T cell activation 
gene 1 (Patarca et al., 1989). Lastly, the name "osteopontin" was proposed for this 
protein which means "bone bridge" (Oldberg et al, 1986). OPN in the human genome is 
positioned at chromosome 4q13 with seven exon (Young et al., 1990). One of these 
exons is non-coding (Hijiya et al.,1994). The most abundant modification of OPN is 
serine phosphorylation as there are 12 serine phosphorylations and one threonine 
modification (Neame and Butler,1996). OPN is now considered as a chemo-attractant and 
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a cytokine molecule with significant roles in apoptosis, inflammation, wound healing and 
tumor metastasis (Giachelli and Steitz, 2000; Chabas, 005). Moreover, it is a key 
cytokine for the induction of T helper type 1 (Th1) cytokines.  
OPN expression is regulated by other cytokines, hormones and various growth 
factors (Sodek et al., 2000). Over expression of OPN is observed in various diseases 
which highlight its importance in these diseases. In rheumatoid arthritis (RA), OPN 
expression is highly increased. One group of researchers concluded that OPN knockout 
mice are protected against RA (Yumoto et al., 2002). However, another group failed to 
demonstrate such association between OPN and RA (Jacobs et al., 2004). Thus, the exact 
role of OPN in RA is still a question mark. OPN over expression is also experienced in a 
verity of cancers including breast, colorectal, lung and stomach. Thus, managing a 
plasma level of OPN will assist in the treatment outcomes of these diseases (Wang et al., 
2000; Wang and Denhardt, 2008). It is established that there exist numerous 
polymorphisms in the promoter region of OPN which influence the immunological 
response to infectious diseases (Patarca et al., 1993; Cantor and Shinohara 2009). 
Over expression of OPN was also observed in inflammatory liver diseases 
(Morimoto et al., 2004). Treatment with OPN neutralizing antibodies reduced 
inflammation related liver injuries (Lund et al., 2009). OPN expression level was also 
accelerated in fulminant hepatitis most probably due to enhanced production from 
macrophages and kupffer cells (Tsutsui et al., 1996). Alcoholic hepatitis also leads to 
enhanced expression of OPN. The high level of OPN was linked with disease severity in 
alcoholic patients (Naveau et al., 2012; Patouraux et al., 2012). Plasma level of OPN may 
be used as a prognostic marker of HBV related hepatocellular carcinoma (Zhao et al., 
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2008). Furthermore, it was also suggested to be a prognostic marker of HCV infection as 
high level of plasma OPN was associated with increased liver cirrhosis and damage 
(Huang et al., 2002). Interferon based therapies of HCV infection were also reported to 
have an association with promoter polymorphisms of OPN. These SNPs were positioned 
at promoter region, -155, -616, -1748 and -442. The most significant association of OPN 
and HCV infection was shown at -442 (Wang et al., 2000; Naito et al., 2005). A recent 
study also demonstrated that OPN polymorphism at -442 may be used as a therapeutic 
marker of combinational therapy of HCV infection (Sakr et al., 2013). 
2.18.6 GALNT8 and HCV Infection 
Probable polypeptide N-acetylgalactosaminyltransferase 8 (GALNT8) is placed in 
the family of O-linked UDP-GalNAcglycosyltransferase (ppGalNTase) (Ten Hagen et 
al., 2003). It participates in the biosynthesis of mucin-like-o-glycan by transferring N-
acetyl-D-galactosamine residue to a serine or threonine residue on a receptor protein. 
Mucin type-o-glycans are associated with a number of glycoproteins. Glycans or sugar 
residues are the important component of most proteins and lipids and serves as a PRRs 
(Varki, 1993). Glycans are essential for the correct folding of proteins in the endoplasmic 
reticulum (ER) (Jentoft,1990), and possessed a role in trafficking of proteins (Ellgaard 
and Helenius, 2001; Helenius and Aebi,  2001). Glycans are also reported for receptor 
function of endogenous structures, cell to matrix or cell to cell interactions (Paulson, 
1989). 
The family of polypeptide GaLNc-transferase is highly conserved as there are 
only 20 isoforms of this enzyme out of 20 - 25000 genes (Bennett et al., 1999). During 
the process of embryo development, each isoform has different spatiotemporal pattern 
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suggesting a unique role of each isoform (Kingsley et al., 2000). The differential 
expression pattern of different isoforms was also observed in adult tissues (Hagen et al., 
2003). The structural analysis of GaLNc-transferase showed that it comprises a short 
cytoplasmic domain, transmembrane domain, a stem region of variable length, a catalytic 
site containing "DXD" motif (Hazes, 1996; Imberty et al., 1997). 
Recently, SNPs of GALNT8 were reported to have an association with interferon 
based therapy of HCV infection in 1088 Japanese population. These patients were given 
interferon monotherapy and a significant association between treatment outcomes and 
GALNT8 SNP in intron 6 (rs2286580) was found. The study was further replicated by 
additional study of 328 patient’s cohort. However, there was found no association of 
rs2286580 polymorphism with the peg-interferon plus ribavirin treatment in chronic 
HCV patients from the same population. The peak association of combinational therapy 
and GALNT8, intron 6 was observed at rs10849138. Thus, SNPs of GALNT8 also have 
an influence on treatment outcomes of HCV infection (Nakano et al., 2013). 
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  Chapter 3 
MATERIALS AND METHODS 
3.1 COLLECTION OF BLOOD SAMPLES  
Informed consent from all patients and healthy controls was taken before their 
enrollment in the current genetic and clinical study. The study was reviewed and 
approved by the ethical committee of Atta-Ur-Rahman School of applied Biosciences 
(ASAB), National University of Sciences and Technology (NUST), Islamabad. The 
patients were recruited in the study from November 2010 to July 2013. The patients were 
selected from two different provinces of Pakistan; Khyber Pakhtunkhwa (KPK) and 
Sindh. Ninety six patients from KPK and ninety patients from Sindh were selected for the 
current study. However, finally we were left with only 75 patients from KPK and 65 
patients from Sindh. Forty five patients were excluded from the current study due to 
incomplete follow up of the patients. 
3.2 PATIENT’S INCLUSION CRITERIA 
 The inclusion criteria of the current study included patients infected with HCV as 
initially confirmed by the detection of HCV antibody in patient’s serum. The levels of 
two markers of liver damage; serum Aspartate aminotransferase and Alanine 
aminotransferse (ALT and AST) were higher than normal level. Moreover, all the 
patients had HCV RNA level higher than 1000 IU/ml as quantified by real time reverse 
transcriptase Polymerase chain reaction qRT-PCR. All enrolled chronic HCV patients 
were treatment naïve. Only those patients were included in the study that had any final 
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fate of therapy and were followed up to six months after the cessation of combinational 
therapy. 
3.3 PATIENT’S EXCLUSION CRITERIA 
Patients with liver damage caused by infection other than HCV, patients co-
infected with other diseases such as HBV, HIV, patients with decompensated liver, 
patients with hepatocellular carcinoma and patients who discontinued the planned course 
of treatment, were all excluded from the current study. 
3.4 STANDARD TREATMENT OF HCV PATIENTS 
The patients were given the treatment of interferon α 2a plus weight based 
ribavirin for at least six months and maximum for one year. 3 million units/0.5ml of 
interferon α 2a was given to the patients three times a week and weight based ribavirin 
800 mg – 1200 mg tablets were given each day. After three months of treatment, patients 
were monitored for viral RNA quantification and the levels of liver enzymes to make 
decision about continuation or discontinuation of combinational therapy. Approximately 
six months after the end of proposed treatment duration, patients were classified into two 
groups, sustained virological responders (SVRs) and non-responders (NRs). SVRs were 
those patients, who were avirimia six months after the cessation of treatment while NRs 
were those patients, who were possessing viral RNA six months after the end of therapy. 
3.5 HEALTHY CONTROLS 
One hundred and twenty healthy controlss were also included in the current study. 
These healthy controls were mostly from Islamabad and cities in vicinity. 
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3.6 STORAGE OF COLLECTED BLOOD SAMPLES 
The blood samples from all chronic HCV patients and healthy controls were taken 
in 5ml K3 ethylene diamine tetra acetic acid (EDTA) tubes (BD vacutainer TM, Franklin 
Lakes, New Jersey, USA) through 5ml sterilized syringes (BD 0.6mm X 25mm, 23 G X 
1 TW, Lahore, Pakistan). The blood samples collected in the field were directly 
dispatched to Viral Hepatitis Laboratories ASAB, NUST, Islamabad (Pakistan). 
Collected samples were stored at 4 degree Celsius (°C) before processing for extraction 
of genomic DNA. 
3.7 DNA EXTRACTION FROM WHOLE BLOOD  
DNA was extracted from the whole blood using commercially available kit 
(Gentra Puregene, Hilden, Germany) by following manufacturer’s instructions. Initially, 
300 µl blood was taken in 1.5 ml centrifuge tube (Axygen®, California, USA), then there 
was added 900 µl RBC lysis buffer. The mixture was left for five minutes incubation at 
room temperature. During the incubation period, the mixture was inverted gently for ten 
times. The mixture was centrifuged for one minute at 13,000 × g by the use of 
microcentrifuge (spectrafuge 24D Labnet, Edison, New Jersey, USA). The supernatant 
was discarded, leaving a white pellet with about 10-15 µl of residual liquid. The pellet 
was vigorously vortexed by means of Reax top (Heidolph, Schwabach, Germany). The 
vortexing was continued until the white pellet was completely disappeared and the cells 
were completely re-suspended in the residual liquid. Then 300 µl cell lysis buffer was 
added and pipetted up and down to lyse the cells. After that the solution was kept for at 
least five minutes to get it cooled. Then 100 µl protein precipitation solution was added 
to the cell lysates and vortexed for half a minute. The mixture was centrifuged at 13,000 
Chapter 3  Materials and Methods 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  52 
 
× g for one minute. Proteins were precipitated in the form of dark brown pellet. 
Supernatant possessing genomic DNA was transferred into another 1.5 ml centrifuge tube 
that already contained 300 µl isopropanol solution. The centrifuge tube was inverted 
multiple times till a clear suspended white thread of DNA was observed. Centrifugation 
was performed at 13,000 × g for two minutes to sediment DNA. The supernatant was 
discarded and the tubes were dried on absorbent paper. After drying, 300 µl of 70% 
ethanol was added to the centrifuge tube and followed by centrifugation at 13,000 × g for 
one minute. Ethanol was poured off, tube was drained on a clean absorbent paper and air 
dried for one hour. DNA hydration solution ranged from 50-100 µl was added, depending 
on quality of DNA and mixed thoroughly by vortexing. DNA samples were stored at -4 
°C for short period and at -20°C for long term storage. 
3.8 QUANTIFICATION OF EXTRACTED DNA 
To find the quality of extracted DNA, 5 µl of extracted DNA sample was run on 
1% agarose gel. 1% (w/v) agarose gel was prepared by melting 0.4g of agarose in 40ml 
of 1X TBE buffer (0.89 M Tris-Borate, 0.032 M EDTA, pH 8.3) in microwave oven for 
one and a half minutes. Ethidium bromide solution (0.5µg/ml final concentration) was 
added to stain DNA. Extracted DNA sample was mixed with a loading dye (0.25% 
bromophenol blue prepared in 40% sucrose solution) and loaded into the wells. 
Electrophoresis was performed at 100 volts for forty minutes in 1X TBE running buffer. 
After electrophoresis, extracted DNA was visualized by placing the gel under UV 
Transilluminator (Biometra, Goettingen, Germany). The extracted DNA was also 
quantified by using Nandrop (Eppendorf Biophotometer, Germany). 
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3.9 PCR FOR THE DETECTION OF SINGLE NUCLEOTIDE 
POLYMORPHISMS 
The list of primers used for the PCR reactions and the size of PCR products are 
shown in table 3.1. Primers were designed manually by first searching the gene sequence 
and then designed primers for the desired SNPs. Three different techniques were used for 
the detection of SNPs in the studied genes. 
3.9.1 Allele Specific Polymerase Chain Reaction (AS-PCR) 
It is a type of selective PCR to detect one of the two alleles of a gene to find out 
SNP. The selective amplification is achieved by designing two forward primers and one 
reverse primer. Let forward primer 1 is for allele "A" and forward primer 2 is for allele 
"B" at a particular position. DNA sample from an individual is taken in two separate 
tubes. In one PCR tube forward primer one, reverse primer and other components of PCR 
mixtures are added. In the second PCR tube forward primer two, reverse primer and other 
components of PCR mixtures are added. If the desired PCR product is amplified only in 
tube 1 then the individual possesses allele "A" at that particular position, if the desired 
PCR product is amplified in tube 2 then the individual possesses allele "B" at that 
particular position. Alternatively, if the desired PCR product is present in both tubes then 
the individual possesses both alleles at that particular position. The difference between 
forward primer 1 and forward primer 2 lies at single nucleotide at 3'-end only. This single 
nucleotide at 3'-end also represents SNP position of that particular gene. Thus, selective 
amplification is achieved by the primer matching or mismatching at one of the two alleles 
at 3'-end of the primer. 
Chapter 3  Materials and Methods 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  54 
 
3.9.2 Amplification Refractory Mutation System Polymerase Chain Reaction 
(ARMS-PCR) 
ARMS-PCR is almost similar to AS-PCR. The only difference is the use of two 
additional primers that serve as an internal control. The reverse primer of an internal 
control serve as reverse primer for allele specific primer 1, allele specific primer 2 and 
internal forward primer. Similar to AS-PCR, an individual DNA sample is taken in two 
different PCR tubes. In PCR tube 1, allele specific primer 1, internal reverse and internal 
forward primer along with other PCR components are used while in PCR tube 2 allele 
specific primer 1, internal reverse and internal forward primer along with other PCR 
components are used. Like AS-PCR, the results are interpreted as; if the desired PCR 
product is present in tube 1 then it contains allele "A". Alternatively, if the desired 
amplification occurs in tube 2 then it contains allele "B". However, if the desired PCR 
product is present in both tubes then the individual contains both alleles and heterozygous 
for that particular genetic mutation. 
3.9.3 Restriction Fragment Length Polymorphism Polymerase Chain Reaction 
(RFLP-PCR) 
RFLP-PCR is a common technique which is used for SNP analysis. This 
technique is based on the fact that SNP usually leads to the creation or abolishment of the 
restriction site of a restriction enzyme (Narayanan, 1991). The first step of RFLP-PCR is 
the amplification of the genomic region spanning the desired SNP. The PCR product is 
digested with the appropriate restriction enzyme that can digest at SNP. The presence or 
absence of the restriction site of the enzyme leads to the production of different size 
products, allele identification can be performed by gel electrophoresis of the digested 
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PCR product. Primers used in the current study for AS-PCR, ARMS-PCR and RFLP-
PCR are shown in the table 3.1. 
Table 3.1: List of primers used for the detection of SNPs 
Gene Primer sequence                                          Product 
size (bp) 
RFLP-PCR primers of IL28B rs8099917 
Forward primer 5′- GTGCATATGTTTTCTGAC -3′ 430 
Reverse primer  5′- GAGGCCCCTCACCCATGC -3′  
RFLP-PCR primers of IL28B rs12979860  
Forward primer 5′- CCAGGGCCCCTAACCTCTGCA -3′ 139 
Reverse primer  5′- GGGAGCGCGGAGTGCAATTCA -3′  
AS-PCR primers of IL28B rs12979860  
Forward primer 5′- AGGGAGCTCCCCGAAGGCGC -3′ 190 
Forward primer 5′- AGGGAGCTCCCCGAAGGCGT -3′  
Reverse primer 5′- CCTATGTCAGCGCCCACAATTCCCA -3′  
AS-PCR primers of TGFβ polymorphism at codon 10  
Forward primer 1 5′-TCCGGGCTGCGGCTGCTGCC -3′ 297 
Forward primer 2 5′-TCCGGGCTGCGGCTGCTGCT-3′  
Common reverse 
primer  
5′-GTCGGCCTCAGGCTCGGGC-3′  
AS-PCR primers of TGFβ polymorphism at codon 25 
Forward primer 1 5′-TACTGGTGCTGACGCCTGGCCG-3′ 254 
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Forward primer 2 5′-TACTGGTGCTGACGCCTGGCCC-3′  
Common reverse 
primer 
5′-GTCGGCCTCAGGCTCGGGC-3′  
AS-PCR primers of OAS1 polymorphism at rs10774671 
Forward primer 5′-TGCAATGCAGGAAGACTCC-3′ 203 
Reverse primer 5′-TGCAGGTCCAGTCCTCTTCT-3′  
AS-PCR primers of IL18 -607 polymorphism 
Common 
forward primer  
5′-TAACCTCATTCAGGACTTCC-3′ 
Sequence 
specific primer 1 5′-GTTGCAGAAAGTGTAAAAATTATTAC-3′ 
196 
Sequence 
specific primer 2 5′-GTTGCAGAAAGTGTAAAAATTATTAA-3′ 
196 
Common reverse 
primer  5′-CTTTGCTATCATTCCAGGAA-3′ 
301 
AS-PCR primers of IL18 -137 polymorphism 
Common 
forward primer  
5′-AGGAGGGCAAAATG CACTGG-3′  
Sequence 
specific primer 1 
5′-CCCCAACTTTTACGGAAGAAAAG-3′ 261 
Sequence 
specific primer 2 
5′-CCCCAACTTTTACGGAAGAAAAC-3′ 261 
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Common reverse 
primer 
5′-CCAATAGGACTGATTAT TCCGCA-3′ 446 
AS-PCR primers of Osteopontin -442 polymorphism 
Reverse primer 1 5′-TTGTTCAAGCCTGCAAGGAGTTCAGAA-3′ 442 
Reverse primer 2 5′-TTG TTCAAGCCTGCAAGGAGTTCAGAG-3′  
Forward primer 5′-GTCCTTAAGATACGCAGAGCATTTGC-3′  
AS-PCR primers of GALNT8 polymorphism in intron 6 at rs10849138 
Forward primer 1 5′-CTGGGTCAGACCTGAAGG-3′ 340 
Forward primer 2 5′-CTGGGTCAGACCTGAAGC-3′  
Common reverse 
primer 
5′-GCACTGGCCTCTAACTTTGGA-3′  
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The major recipe of PCR mixture used for the analysis of all SNPs is shown following. 
Nuclease free water (RO582, Fermentas, USA) 12 µl 
Taq buffer 2.5 µl 
2mM dNTPs 2.5 µl 
2.5mM MgCl2 2.5 µl 
Forward Primer 1 (10 pmole) 1 µl 
Forward Primer 2 (10 pmole) 1 µl 
Reverse Primer (10 pmole) 1 µl 
DNA template 2 µl  
Taq Polymerase (EP0402, Fermentas, USA) 0.5 µl 
Total volume 25 µl 
 
PCR condition of all reactions is shown in the Figure 3.1. 
 
 
 
 
 
 
 
 
Figure 3.1: PCR conditions of all reactions 
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3.10 VIRAL RNA EXTRACTION  
  HCV RNA was extracted by the use of RTA
®
 Viral RNA Isolation Kit (Catalog 
No. 09006100). The frozen serum samples were thawed at room temperature. 6 μl of 
carrier RNA was taken in a 1.5 ml eppendrof tube followed by the addition of 600 μl RL 
(RBC lysis buffer) and 150 μl serums. The mixture was mixed properly by pulse-
vortexing for 20 times. The mixture was kept at room temperature for ten minutes. After 
a brief centrifugation, there was added 600 μl pure ethanol and pulse shaked for twenty 
times following a brief centrifugation. 700 μl of the mixture was transferred into the 
column placed in a collection tube. The solution was centrifuged at 10,000 × g for one 
minute, collection tube was discarded. The column was placed in a new collection tube 
and the remaining 700 μl mixture was transferred into it followed by a centrifugation. 
Again, the collection tube was discarded. The column was placed in a new collection tube 
for the step of washing. 700 μl of washing buffer 1 was added to the column followed by 
centrifugation at 10, 0000 × g for one minute. The collection tube was discarded. The 
column was placed in other collection tube; there was added 700 μl washing buffer 2 
followed by the centrifugation at 14,000 × g for one minute. The spin column was placed 
in a new eppendrof tube of 1.5 ml and there was added 50-100 μl of solution E followed 
by incubation at room temperature for 3 min. Finally, the spin column was centrifuged at 
14,000 rpm for one minute. The spin column was discarded. The eppendrof tube 
containing viral RNA was kept at -20˚C for short term storage and at -80 ˚C for long term 
storage. 
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3.11 HCV GENOTYPING 
The extracted RNA was used for the cDNA synthesis. The final PCR reaction 
mixture of 20 µl contained 10 µl extracted RNA possessing approximately 50 ng RNA, 
1.87 µl  RNase free water, 1x MMLV buffer, 400 µM dNTPs, 10 units of RNase inhibitor 
(fermentas), 20 units of Moloney murine leukemia virus reverse transcriptase enzyme 
(M-MLV RTaseFermentas), and 20 pM of antisense primer. The se uence of antisense 
primer was was 5 -GAGACGGGTATAGTACCCCATGAGAGTCGGC-3 . The PCR was 
performed by AB Veriti 96 well thermocycler and cycling condition was; incubation at 
37°C for 55 minutes and then followed at 95°C for 5 minutes. Synthesized cDNA was 
stored at 4°C. 
3.11.1 First Round PCR (Genotyping) 
4  l of the synthesized cDNA was used for first round PCR of HCV genotyping. 
Forward primer was  5 -GGGAGGTCTCGTAGACCGTGCACCATG-3 and reverse 
primer was  5 -GAGACGGGTATAGTACCCCATGAGAGTCGGC-3 . The reaction 
mixture contained; 2x M-MLV buffer, 200 µM dNTPs, 3 mM MgCl2, 8.2 µl RNase free 
water, 20 pM of each primers (Forward and Reverse) and 2 units of Taq polymerase 
enzyme (Fermentas). Cycling condition was; incubation at 94°C for 05 minutes followed 
by 25 cycles, each cycle was; incubation at 94°C for 45 s, at 52°C for 45 s, at 72°C for 55 
s. The final extension was performed at 72°C for 07 min. 
3.11.2 Second Round PCR (Genotyping) 
The first round product was used in the second round. There were used two 
separate PCR tubes for Mix1 and Mix2 primers. Mix1 and Mix2 were mixtures of 
primers. The primers contained in each mixture are shown in table 3.1. The primers of 
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Mix1 were specific for genotype 1b, 3b, 2a, 2b, while the primers of Mix2 were specific 
for genotype 1a, 3a, 5a, 6a and 4.  Each mixture contained 20 pm of each respective 
primer in both Mix1 and Mix2. 
Table 3.2: List of primers used for HCV genotyping. 
Name Mix 1 primers Name Mix 2 primers 
 
S7 
 
AGACCGTGCACCATGAGCAC 
 
S7 
 
AGACCGTGCACCATGAGCAC 
S2a AACACTAACCGTCGCCCACAA G1a GGATAGGCTGACGTCTACCT 
G1b CCTGCCCTCGGGTTGGCTAAG G3a GCCCAGGACCGGCCTTCGCT 
G2a CACGTGGCTGGGATCGCTCC G4 CCCGGGAACTTAACGTCCAT 
G2b GGCCCCAATTAGGACGAGAC G5a GAACCTCGGGGGGAGAGCAA 
G3b CGCTCGGAAGTCTTACGTAC G6a GGTCATTGGGGCCCCAATGT 
 
For both mixtures, the PCR receipe was; 2 units of Taq polymerase enzyme (Fermentas), 
20 pm of each primers, 2x M-MLV buffer, 200 µM dNTPs, 3 mM MgCl2, 3.2 µl RNase 
free water, and 5 µl of template (first round product). The reaction condition was; 
denaturation at 95˚C for 5 minutes followed by 25 cycles of denaturation at 94˚C for 45 
sec, annealing at 52˚C for 45 sec, extension at 72˚C for 45 sec. The final extension was 
performed at 72˚C for 10 min. Finally, the amplified product was run on 3% agarose gel 
with commercially available DNA marker (Fermentas). Products of HCV genotypes were 
visualized under UV light of the gel documentation system (Wealtec) and compared with 
100-bp DNA marker. 
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3.12 VIRAL LOAD DETERMINATION 
40 μl of Master Mix was added to 10 μl of RNA template or positive control into 
100 μl PCR tube. The PCR tubes were properly closed and centrifuged briefly. Then the 
tubes were placed in PCR machine. The PCR program was run according to the 
following conditions. 
Table 3.3: Real Time PCR Thermal Cycling Conditions 
STEPS  TEMPERATURE  TIME  
Reverse Transcription 42 ˚C 5.00 min 
Initial Denaturation 95 ˚C 10 sec 
Denaturation 95 ˚C 5 sec 
Annealing Extension  58 ˚C 40 sec 
Extension 72 ˚C 10 sec 
Fluorescence Detection FAM, JOE  
Number of Cycles 50  
 
3.13 STATISTICAL ANALYSES 
Statistical analysis of the data was performed by SPSS software version 13. Age 
of the individuals in healthy control group, SVR group and NR group was taken as 
mean±SD. Independent T-test was applied on age to find any correlation with treatment 
response to interferon based therapy of HCV infection. Viral load of HCV was taken as 
range and median. Independent T-test was applied on viral load to find any association of 
viral load with interferon based therapy of HCV infection. Phi coefficient test was 
applied to explore any correlation of treatment response of HCV infection with age. 
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Hardy-Weinberg equilibrium was applied on the distribution of SNPs to find the expected 
frequencies of various genotypes in the studied population. Pearson chi square analysis 
was applied on the observed distribution frequencies of different genotypes in the 
enrolled subjects. A P-value ≤ 0.05 was considered to be statistically significant. 
3.14 BIOINFORMATIC ANALYSES FOR GENETIC POLYMORPHISM 
The single nucleotide genetic variations were identified by putting the number of 
RefSNP (rs) of each SNP in National Centre for Biotechnology Information (NCBI) 
database. After approaching the gene sequence, there were designed primers manually. 
The primers were checked for their specific binding by Primer-blast software. Moreover, 
a theoretical restriction map program of online software Webcutter V2.0 was used to find 
the restriction sites of the restriction endonucleases and the size of the digested product. 
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          Chapter 4 
RESULTS 
4.1 DEMOGRAPHIC PROFILES OF PATIENTS 
  Initially, 186 chronic HCV patients were enrolled for the present study but finally 
140 patients completed the proposed duration of combinational therapy of interferon and 
ribavirin and possessed any final fate of therapy. There were 115 chronic HCV patients 
(72 male and 43 female) that were categorized as sustained virological responders 
(SVRs) with the mean age of 36.28±12.11. Twenty five chronic HCV patients (11 male 
and 14 female) were classified as non responders (NRs) with the mean age of 
37.32±8.24. There was no significant difference in the age of responders and non 
responder groups (P = 0.608). One hundred and twenty healthy controls (60 male and 60 
female) with the mean age of 25.11±8.21 were also considered in this study. There was a 
significant variability in the baseline viral load of SVRs and NRs group (P = 0.241). 
Statistical analysis of other clinical parameters of chronic HCV patients showed that there 
was a significant variation in baseline Alanine transaminase (ALT) level of the responder 
and non-responder group of patients (P = 0.001). Regarding other clinical parameters; 
serum glutamic oxaloacetic transaminase or aspartate aminotransferase (SGOT or AST) 
level and bilirubin level, we found no significant differences in responder and non 
responder group of patients. The P value in the two groups of patients for SGOT level, 
ALT level and bilirubin levels were 0.267, 0.347 and 0.420 respectively as shown in table 
4.1. 
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Table 4.1 Demographic profiles of patients and healthy control controls. 
 
 
 
 
Variables 
 
SVRs 
 
NRs 
Healthy 
Controls 
P 
Values 
Numbers 115 
 
25 
 
120 - 
*Age 
 
36.28±12.11 
 
37.32±8.24 25.11±8.21 0.608 
Gender 
72 male; 43 
female 
 
11 male; 14 
female 
 
60 male; 60 
female 
0.086 
**Baseline viral load 
 
1.11X10
5
 
(0.045x10
5
 - 
54.7x10
5 
 
5.64X10
5
 
(0.4x10
5
 - 
98.7x10
5
) 
- 0.241 
 
Baseline alanine 
aminotransferase (IU/L 
 
66.3±33 90.3±33.6 - 0.001 
 
Base line SGOTM 
(IU/L) 
 
72.6±42 82.5±30 - 0.267 
 
Alkaline phosphatase 
(U/L) 
 
311.5.6±143 340 ±105.1 - 0.347 
 
Bilirubin level (mg/dl) 
 
1.3±0.87 1.4 ±0.86 - 0.420 
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4.2 HCV GENOTYPING 
There are 11 major HCV genotypes with more than 100 sub-genotypes (Safi et 
al., 2012). HCV genotyping is very imperative from the patients’ point of view as 
different HCV genotypes respond in a different way to combinational therapy of 
interferon and ribavirin. Thus, HCV genotyping is significant for clinical management of 
infection. The distribution of HCV genotypes varies from region to region (Idrees et al., 
2008). Type 1a and 1b are the most prevalent HCV genotypes worldwide, particularly in 
United States of America and Japan (Ashfaq et al., 2011). HCV genotype 2 is mostly 
distributed in North America and Europe. HCV Genotype 3 is mostly distributed in East- 
South Asia while in middle East, Egypt and central Africa, HCV genotype 4 is most 
commonly present (Kamal and Nasser, 2008). HCV genotype 5 is common in South 
Africa. HCV genotype 6 is prevalent in Hong Kong (Chao et al., 2011), while 7, 8, 9 are 
common in Vietnamese population. HCV Genotype 10 and 11 are acknowledged in 
Indonesian population (Lavanchy, 2011). 
HCV genotyping was performed by Ohno as described in chapter 2. Firstly, HCV 
RNA was extracted according to the manufacturer’s instruction. Extracted RNA was used 
to synthesize cDNA. The first round and second PCR were performed using different sets 
of primers as shown in table 3.2. The second round PCR product is shown in Figure 4.1. 
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Figure 4.1: Electrophoretic analysis of HCV genotypes of five patients. Patient’s numbers are 
represented by "Numerals". Products in lane number 1 and 5 represent HCV genotype 2a 
(product size190bp, in Mix1). Lane 2 represents genotype 1a (product size 208-bp in Mix 2). 
Lane number 3 and 4 indicate HCV genotype 3a (Product size 232bp, in Mix 2). 
4.2.1 HCV Genotypes in the Present Study  
The current study demonstrated that most of the patients were infected with HCV 
genotype 3 and then genotype 1. Further classification into sub genotypes showed that the 
distribution of sub-genotype 3a and sub-genotype 3b was 56.4% and 15% respectively. 
The prevalence of sub-genotypes 1a and 1b were 10% and 3.57% respectively while the 
prevalence of untypeable and co-infection patients were 6.42% and 7.14% respectively as 
shown in Figure 4.2.  There were no significant variations in the distributions of HCV 
genotypes in the two provinces (KPK and Sindh) of Pakistan. 
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Figure 4.2: Percentage distributions of HCV genotypes in present study. The frequency of 
HCV patients for genotypes; 3a, 1a, 3b, 1b untypeable, coinfection and 4 were 79 (56.4%), 14 
(10%), 21 (15%), 5 (3.5%), 9 (6.42%), 10 (7.1%), 2 (1.4%) respectively. Regarding 10 co-
infected patients, two patients were infected with genotype 3a plus 1b, one patient with 3a plus 1a 
while six patients were infected with 3a plus 3b. 
4.2.2 Treatment Response Rates of Different HCV Genotypes 
 Owing to its RNA genome, HCV has acquired the capability of genetic 
variability. Within all chronic HCV patients, there are evolved slightly different genetic 
variants of HCV known as quasi-species. Genotypes represent major genetic differences 
while quasi-species represent minor genetic differences within individuals (Bukh et al., 
1995). HCV quasi-species are spontaneously evolved over the time in response to the 
host immune pressure and treatment response.  It is well established that HCV quasi-
species are stable and tend to increase in treatment non-responders while in treatment 
responders, the number of quasi-species decreases (Puig-Basagoiti et al., 2005). 
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Since the past decade the gold standard treatment of HCV infection is interferon 
plus ribavirin. Response to interferon based therapy of HCV infection is mostly 
dependent on HCV genotype. Response rate to combinational therapy of HCV infection 
for HCV genotype 2 and 3 is approximately 80%, while for HCV genotype 1 the 
treatment response rate is 40% - 52% (Zeuzem et al., 2006). In Pakistani population also, 
treatment response to HCV genotype 1 and 4 is poor while response rate for genotype 3 is 
high (Idrees et al., 2008).   
In the current study collectively 140 HCV patients from Swat (KPK) and Gambatt 
(Sindh) were genotyped for HCV infection. Out of these 140 patients 115 patients were 
SVRs and 25 were NRs. The response rate to combinational therapy of HCV infection is 
shown in Figure 4.3. 
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Figure 4.3: Percentage response rates of different HCV genotypes to interferon plus 
ribavirin treatment. The response rate to interferon based therapy of HCV infection was 
maximum for HCV genotype 3 and 4. However, there were only two patients of HCV genotype 
4. Therefore, its response rate to therapy is not significant. Most of the patients were infected with 
HCV genotype 3 and they showed high response rate to HCV infection i.e. 91% and 86% for 
genotype 3a and 3b respectively. Response rate to HCV co-infection was also high (60%). The 
most possible reason may be the involvement of HCV genotype 3 with other HCV genotypes. In 
the current study, response rate to HCV genotype 1 was minimum (57%). 
4.3 HOST GENETIC VARIATIONS AND COMBINATIONAL 
THERAPY OF HCV INFECTION 
Since the discovery of HCV infection in 1989, there is still a continuous effort for 
the discovery of new HCV treatment options. In almost all these treatment options of 
HCV infection, there is still a significant involvement of interferon. The antiviral activity 
of interferon is also dependent on viral and host genetic variations. Therefore, the aim of 
the study was to search for important host SNPs that may significantly predict success 
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rate of combinational therapy of HCV infection in Pakistani population. The association 
of; IL28B rs12979860 and rs8099917, TGF-β1 functional polymorphism at codon 10 T/C 
(rs1982073) and codon 25 G/C (rs1800471), OAS1 genetic mutation at rs10774671, IL18 
promoter variants, -607C/A (rs1946518) and -137G/C (rs187238), OPN promoter 
polymorphism, -442 C/T (rs11730582), a single nucleotide variant in intron 6 of 
GALNT8 rs10849138 were considered with combinational therapy of HCV infection in 
the current study. 
4.4 ANALYSIS OF IL28B rs12979860 POLYMORPHISM BY ALLELE SPECIFIC 
POLYMERASE CHAIN REACTION  
IL28B also known as interferon λ (IFN- λ3) belongs to type III IFNs (Imran et al., 
2013a). Antiviral activity of IFN-λ is less than IFN-α but it possesses a critical role in 
fighting against viruses. The two main SNPs identified as the strongest predictor of 
spontaneous clearance and treatment responders to interferon based therapy of HCV 
infection were rs12979860 (3 kb upstream of the IL28B gene) and rs8099917 (8 kb 
upstream of IL28B gene) (Ank et al., 2006; Coccia et al., 2004; Thomas et al., 2009). 
To study the significance of IL28B rs12979860 in combinational therapy of HCV 
infection in the current study, allele specific polymerase chain reaction (AS-PCR) was 
performed. Initially, DNA was extracted from the blood samples of both healthy controls 
and chronic HCV patients. The quality of DNA was testified both by running DNA on 
1% agarose gel and also by Nanodrop. The extracted DNA was amplified by a set of two 
primers that were allele specific in two separate PCR tubes. One set of primer was 
forward primer 1 and reverse primer (FP1+RP) while the other set of primers was 
forward primer 2 and reverse primer (FP2+RP). The reverse primer of both sets was 
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same. In forward primer 1 and forward primer 2 there was only a single nucleotide 
difference at 3׳-end. PCR amplified product was run on 2% agarose gel and visualized 
under UV light by gel documentation system (Figure 4.4). 
 
 
 
 
 
 
 
 
 
Figure 4.4: Detection of IL28B rs12979860 genetic variation by AS-PCR. Digital print out of 
agarose gel showing AS-PCR amplification of IL28B rs12979860 polymorphism of two 
individuals. The first individual represented by lane 1 and 2 is homozygous for T allele (product 
size 190bp). The second individual represented by lane 3 and 4 is heterozygous. 
4.4.1 Analysis of IL28B rs12979860 Polymorphism by Restriction Fragment Length 
Polymorphism Polymerase Chain Reaction (RFLP-PCR)  
To check out the consistency of results obtained by AS-PCR amplification of IL28B 
rs12979860, RFLP-PCR analysis was also performed. The extracted DNA was subjected 
to PCR amplification by a single set of primers. The PCR product was digested with 
BstU-I restriction endonuclease (New England Bio-labs, Hitchin, UK) for 4 hours. The 
10 µL digested product was run on 3% agarose gel along with 100-bp ladder and 
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visualized under UV light of gel documentation system as shown in the Figure 4.5. The 
digested product was represented by products of 109-bp and 39-bp. As the product size of 
39-bp is smaller, so therefore it was not shown and only 109-bp product was visualized. 
If the digestion not occurred by restriction enzyme, then a single band of 139-bp was 
shown. On the other hand, if the individual was heterozygous then all the three products 
(139, 109, 30bp) were observed. 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Detection of IL28B rs12979860 genetic variation by RFLP-PCR. Digital print out 
of agarose gel representing RFLP-PCR amplification of IL28B rs12979860 polymorphism in 
three individuals. Lane 1 represents homozygous CC individual (product size: 109bp). Lane 2 
represents homozygous TT individual (product size: 139bp). Lane 3 represents heterozygous CT 
individual (product size: 109bp + 139bp).  
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4.4.2 Distribution of IL28B rs12979860 genotypes in healthy controls and chronic 
HCV patients 
The distribution of IL28B rs12979860 CC, CT and TT genotypes in healthy controls and 
chronic HCV patients was; 48 (40%), 58 (48%), 14 (12%) vs 51 (36%), 68 (49%), 21 
(15%) respectively. These Figures showed that there is no significant association of any 
IL28B rs12979860 genotype with the spontaneous clearance of HCV infection.  
 
 
 
 
 
 
 
 
 
Figure 4.6: Percentage distribution of IL28B rs12979860 genotypes in healthy controls and 
chronic hepatitis C patients. The prevalence of IL28B rs12979860 genotypes; CC, CT and TT 
in healthy controls was 40%, 48%, and 12% respectively while their distribution in chronic HCV 
patients was 36%, 49% and 15% respectively. 
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4.4.3 Association of IL28B rs12979860 Polymorphism with Interferon Based 
Therapy 
Chronic HCV patients were categorized into two groups on the basis of response to 
interferon based therapy of HCV infection. The SVR group was comprised of 115 
chronic HCV patients, while in NR group there were 25 chronic HCV patients. The 
distribution of CC, CT and TT genotypes in SVR and NR groups was; 47 (41%), 53 
(46%), 15 (13%) and 4 (16%), 15 (60%), 6 (24%) respectively. Pearson chi square 
analysis by SPSS software version 13 showed that the P values were; 0.019, 0.207 and 
0.164 for IL28B rs12979860CC, CT and TT genotypes. These analysis demonstrated that 
patients possessing CC genotype at rs12979860 were positively associated with the 
treatment response (P = 0.019). The other two genotypes i.e. CT and TT were not 
statistically noteworthy in SVRs and NRs (Figure 4.7). 
 
 
 
 
 
 
 
 
Figure 4.7: Percentage distributions and P-values of IL28B rs12979860 genotypes in SVRs 
and NRs. Pearson chi square test was applied to find the P-values. The P-values for IL28B 
rs12979860; CC, CT and TT were 0.019, 0.207 and 0.264 respectively. 
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4.5 ASSOCIATION OF IL28B rs8099917 WITH COMBINATIONAL 
THERAPY OF HCV INFECTION 
The IL28B rs8099917 polymorphism is also known to possess a role in interferon 
based therapy of HCV infection. This SNP is determined to mainly dependent on 
ethnicity also. For IL28B rs8099917, treatment favorable allele is "T" and treatment 
unfavorable allele is "G". Moreover, IL28B rs8099917 polymorphism have an impact on 
the mRNA expression of IL28B describing its possible role in the regulation of intra-
hepatic expression of interferon stimulated genes (ISGs) (Suppiah et al., 2009; Tanaka et 
al., 2009). The polymorphism of IL28B rs8099917 in the current study was determined 
by RFLP-PCR method. Initially, genomic DNA was extracted from blood by kit method. 
The DNA was amplified by PCR. The amplified product was digested by BseMI (BsrDI) 
restriction endonuclease (Fermentas, Vilnius, Lithuania) for four hours. 10 µL of digested 
product was analyzed on 3% agarose gel along with 100-bp ladder (Fermentas, Vilnius, 
Lithuania) and observed under UV light of the Wealtec gel documentation system as 
shown in Figure 4.5. The digested product generated two products indicated homozygous 
GG subject while in case of heterozygous subject there were produced three products. 
The un-digested RFLP-PCR product showed homozygous TT subject. 
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Figure 4.8: Detection of IL28B rs8099917 genetic variation by RFLP-PCR. Amplification of 
IL28B rs8099917 polymorphism in three different individuals. Lane 1 represents homozygous TT 
individual (band size 430bp). Lane 2 represents homozygous GG individual (band size 175bp + 
255bp). Lane 3 represents heterozygous TG individual (band size 430bp+255bp + 175bp). 
4.5.1 Distribution of IL28B rs8099917 Polymorphism in Chronic HCV Patients and  
Healthy Controls 
The distribution of IL28B rs8099917 TT, TG and GG genotypes in healthy 
controls and chronic hepatitis C (CHC) patients was; 39 (32%), 64 (53%), 17 (14%) and 
47 (34%), 68 (48%), 25 (18%) respectively. These Figures showed that there is no 
significant differences in  the distribution  of any genotype in healthy controls and CHC 
patints. Thus, IL28B rs8099917 genotypes were not linked with the the spontenous 
clearance of HCV (Figure 4.9). 
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Figure 4.9: Percentage frequencies of IL28B rs8099917 genotypes in healthy controls and 
chronic hepatitis C patients. The prevalence of IL28B rs8099917 genotypes TT, TG GG in 
healthy controls was; 32%, 53%, 14% while in chronic HCV patients it was 34%, 48%, 18% 
respectively.  
4.5.2 Distribution of IL28B rs8099917 Polymorphism in SVR and NR Patinets 
To find the effect of interferon based therapy on HCV infection, the prevalance of 
of IL28B rs8099917 in SVR and NR groups was analyzed by Pearson chi square test. The 
distribution of IL28B rs8099917TT, TG and GG genotypes in SVR and NR groups was; 
41 (36%), 55 (48%), 19 (16%) and 6 (24%), 13 (52%), 6 (24%) respectively. The P 
values for all the three genotypes showed no significance (Figure 4.10). 
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Figure 4.10: Percentage frequencies and P-values of IL28B rs8099917 genotypes in SVRs 
and NRs. P-values were find by Pearson chi square test. P-values for IL28B rs8099917 
genotypes; TT, TG and GG were, 0.264, 0.705 and 0.376 respectively. 
 
 
 
 
 
 
 
 
 
Chapter 4  Results 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  80 
 
4.6 TRANSFORMING GROWTH FACTOR (TGF)-β 
Transforming growth factor (TGF)-β is anti-inflammatory cytokine that 
suppresses the development and cytotoxicity of natural killer (NK) cells. It blocks the 
production of IFN-γ and IL12. SNPs of TGF-β are associated with variable production of 
this cytokine (Grainger et al., 1999), liver cirrhosis (Okumoto et al., 2004), and natural 
clearance of virus (Kimura et al., 2006). We studied the correlation of TGF-β functional 
polymorphism at codon 10 and 25 with the natural clearance and treatment response of 
HCV infection in 140 chronic HCV patients and 120 healthy controls. 
4.6.1 Detection of TGFβ Codon 10 Polymorphism  
The correlation of TGF-β functional polymorphism at codon 10 with interferon 
based therapy of HCV infection in Pakistani patients was investigated by AS-PCR. DNA 
was extracted from the whole blood and amplified for the desired gene by AS-PCR. The 
amplified product was run on 2% agarose gel and observed under gel documentation 
system as shown in Figure 4.11. 
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Figure 4.11: AS-PCR amplification of TGFβ codon 10 amplification. Lane M represents 100-
bp ladder. Lane 1 and 2 represent homozygous individual for TT genotype at TGFβ codon 10 
functional polymorphism. Lane 3 and 4 represent heterozygous individual for TGFβ codon 10 
polymorphism.  
4.6.2 Distribution of TGFβ codon 10 polymorphism in healthy controls and chronic 
hepatitis C patients. 
The distribution of TGFβ codon 10 genotypes; TT, CT, CC in 120 healthy 
controls and 140 chronic HCV patients was 34 (28.30%), 66 (55%), 20 (16.60%) and 46 
(32.80%), 74 (52.80%), 20 (14.20%) respectively. There were no significant variations in 
distribution of any TGFβ codon 10 genotypes in SVRs and NRs group. Thus, the results 
suggest that there is no association of TGFβ codon 10 polymorphism with the natural 
clearance of HCV infection (Figure 4.12).  
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Figure 4.12: Distribution comparison of TGFβ polymorphism at codon 10 in healthy 
controls and chronic hepatitis C patients. The percentage distribution of TGFβ codon 10 
genotypes TT, TC and CC in healthy controls was; 28.30%, 55%, and 16.60% respectively. In 
chronic HCV patients, the prevalence of TGFβ codon 10 genotypes  TT, TC and CC was; 
32.80%, 52.80% and 14.20% respectively.  
4.6.3 Effect of TGFβ codon 10 polymorphism on interferon based therapy of HCV 
infection. 
Our results suggest that the distribution of TGFβ codon 10 genotypes  TT, CT and 
CC in SVRs and NRs group was; 38 (33%), 62 (54%), 15 (13%) and 8 (32%), 12 (48%), 
5 (20%) respectively. Furthermore, Pearson chi square test showed that TGFβ codon 10 
genotypes have no association with the treatment response of HCV infection as the P 
values for all genotypes were greater than 0.05 (Figure 4.13). 
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Figure 4.13: Percentage frequencies and P-values of TGFβ codon 10 polymorphism in SVRs 
and NRs. The percentage distribution of TGFβ codon 10 genotypes  TT, CT and CC in 115 SVR 
patients was 33%, 54%, and 13% respectively. The prevalence of TGFβ codon 10 polymorphism 
genotypes; TT, CT and CC, in 25 NR patients was 32%, 48%, and 20% respectively. 
4.7 AMPLIFICATION OF TGFβ CODON 25 POLYMORPHISM 
Initially, DNA was extracted from the whole blood of 120 healthy control and 140 
chronic HCV patients. Genomic DNA was amplified by a set of allele specific primers. 
Amplified PCR product was run on 2% agarose gel and observed under UV light of gel 
documentation system (Figure 4.14). 
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Figure 4.14: Agarose gel representing AS-PCR amplification of TGFβ codon 25 of three 
individuals. Lane M represents 100-bp ladder. Lane 1, 2, 3 and 4 represent two heterozygous 
individual while lane 5 and 6 are representing homozygous individual. TGFβ codon 25 
amplification was performed for 140 chronic HCV patients and 120 healthy controls. 
4.7.1 Distribution of TGFβ codon 25 Polymorphism in Healthy Controls and CHC 
Patients 
The prevalence of TGFβ codon 25 genotypes GG, GC and CC in healthy controls 
and chronic HCV patients was; 55 (45.80%), 48 (40%), 17 (14.10%) and 69 (49.20%), 53 
(37.80%), 18 (12.80%) respectively as shown in Figure 4.15. Pearson chi square test 
showed that the P values for GG, GC and CC genotypes were all greater than 0.05 and 
insignificant. The results suggest that there is no role of any TGFβ codon 25 genotypes in 
the natural clearance of HCV infection. 
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Figure 4.15: Distribution variations of TGFβ polymorphism at codon 25 in healthy controls 
and chronic hepatitis C patients. The prevalence of TGFβ polymorphism at codon 25 in healthy 
control was; 45.80%, 40%, and 14.10% for genotypes, GG, GC and CC respectively. The 
distribution of TGFβ polymorphism at codon 25 in chronic HCV patients was; 49.20%, 37.80%, 
and 12.80% for TGFβ codon 25 genotypes, GG, GC and CC respectively. 
 
4.7.2 Association of TGFβ codon 25 Polymorphism with Treatment Response of 
HCV Infection 
The distribution of TGFβ codon 25 genotypes; GG, GC, CC in SVRs and NRs 
group was; 59 (51%), 44 (38%), 12 (36%) and 10 (40%), 9 (36%), 6 (24%) respectively 
(Figure 4.16). Pearson chi square analysis showed that P values for all the genotypes 
were greater than 0.05. It can be inferred that there is no association of TGFβ codon 25 
polymorphism with interferon based therapy of HCV infection in the current study. 
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Figure 4.16: Percentage frequencies and P-values of TGFβ codon 25 polymorphism in SVRs 
and NRs. The prevalence of TGFβ codon 25 genetic variations was demonstrated for 115 SVR 
chronic HCV patients and 25 non-responder chronic HCV patients. The P-values were calculated 
by Pearson chi s uare analysis. The P values for TGFβ codon 25 genotypes GG, GC and CC 
were, 0.306, 0.833 and 0.066 respectively. 
4.8 DETECTION OF OAS1 -442 GENE POLYMORPHISM 
OAS1 gene has antiviral activity but there are a lot of variations in its sequence. 
Approximately, 36 SNPs have been noted in OAS1 gene. The strongest SNP of OAS1 
antiviral activity is present at exon 7 SAS (rs10774671). This genetic variation is also 
suggested to have a significant role in type 1 diabetes (Bonnevie-Nielsen et al., 2000). 
The normal splicing at exon 7 of OAS1 gene is achieved by the presence of AG sequence 
at this site. The "G" allele at this position retains the splice site and confers higher 
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enzymatic activity, (p46) whereas the presence of "A" allele at this postion (AA at 
acceptor site) ablates the splice site and confers lower enzymatic activity (p48 and p52) to 
OAS1 gene (Bonnevie-Nielsen et al., 2005; King et al., 2002). Thus, the genetic variation 
at exon 7 SAS of OAS1 renders it the characteristic of an excellent candidate gene that 
can significantly predicts the response to IFN based therapy in HCV or HBV patients 
(King et al., 2002; Suzuki et al., 2004). 
The role of this important antiviral gene was analyzed by RFLP-PCR. Firstly, the 
genomic DNA was extracted and then amplified by a set of RFLP primers. 8 µL of the 
amplified product was digested by AluI enzyme in a total volume of 20 µL. 10 µL of the 
digested product was run on a 3% of agarose gel. The electrophoresed product was 
observed under UV light of Wealtec gel documentation system. The presence of AA 
genotype in a subject was confirmed by complete digestion of the amplified product into 
two fragments; 150 bp and 53 bp. The presence of GG genotype was shown by no 
digestion while heterozygous (AG) condition at the exon 7 SAS of OAS 1 gene was 
demonstrated by three fragments of; 203-bp, 150-bp and 53-bp (Figure 4.17). 
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Figure 4.17: Electrophoresis patterns of OAS1 gene of three different individuals by RFLP-
PCR. Lane 1, 150bp and 53bp products represent homozygous allele "A". 203bp product in lane 
2 represents homozygous "G" allele. Lane 3, 203bp 150bp and 53bp products represent 
heterozygous A/G alleles of OAS1 gene polymorphism. 
4.8.1 Frequency of OAS1 Genotypes in Healthy Controls and Patients Group 
One hundred and twenty healthy controls and one hundred forty chronic HCV 
patients from both sexes were enrolled in the current study to find the importance of 
genetic testing of OAS1 gene. The frequency of OAS1 gene polymorphism at exon 7 
SAS was studied in healthy controls and chronic HCV patients. The prevalence of OAS1 
genotypes GG, GA and AA in healthy controls was; 74 (62%), 40 (33%), and 6 (5%) 
respectively. The distribution of OAS1 genotypes GG, GA and AA in chronic HCV 
patients was; 97 (69%), 35 (25%) and 8 (6%) repectively as shown in Figure 4.18. The 
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results suggest that "G" allele (70%) tends to be more frequent than "A" allele (30%) in 
both control and infected individuals. The prevalence of all genotypes in both groups was 
comparable. Thus, there is no role of OAS1 SAS at exon 7 polymorphism in spontaneous 
clearance of HCV infection. 
 
 
 
 
 
 
 
 
 
Figure 4.18: Comparison of percentage distributions of OAS1 gene in healthy controls and 
chronic hepatitis C patients. The prevalence of OAS1 genotypes GG, AG and AA in healthy 
controls was; 62%, 33%, and 5% respectively. The occurrence of OAS1 genotypes GG, AG and 
AA in chronic HCV patients was; 69%, 25%, and 6% respectively. 
4.8.2 Distribution of OAS1 Genotypes in SVR and NR Groups 
The group of chronic HCV patient was further classified into SVR and NR to 
reveal any correlation of OAS1 polymorphism with interferon based therapy of HCV 
infection in Pakistani population. Pearson Chi square analysis was performed to compare 
the two groups. The prevalence of GG genotype was significantly higher in SVR group 
than NR group (N = 84 vs N = 13; P value: 0.039). The frequency of the other two 
genotypes of OAS1 gene i.e. AG and AA were almost similar in both SVR and NR 
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groups representing a non-significant P value (Figure 4.19). The high occurrence of GG 
in SVR group demonstrated that individuals possessing this genotype at exon 7 SAS of 
OAS1 gene are better responders to interferon based therapy of HCV infection. 
 
 
 
 
 
 
 
 
 
Figure 4.19: Comparison of P-values and percentage variations of OAS1 gene in responder 
and non-responder groups. Pearson chi square test was applied to find the P-values. The P-
values for OAS1 exon 7 SAS genotypes; GG, AG and AA were 0.039, 0.161 and 0.138 
respectively. 
4.9 INTERLEUKIN-18 POLYMORPHISM 
Interleukin 18 (IL18) is inflammatory cytokine that is mainly produced by 
immature dendritic cells, monocytes and macrophages. It induces the production of two 
important cytokines, TNF-α and IFN-γ (Zecchina et al., 2001). Up-regulation of IL18 
possesses a role in hepatic injury (Vecchiet et al., 2005), and a weak treatment response 
to interferon therapy (Asakawa et al., 2006). The two strong SNPs of IL18 that regulate 
its production are -607 C/A and -137 G/C. These SNPs are reported to influence 
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interferon based therapy of HCV (Manohar et al., 2009), HBV (Kimura et al., 2002; Yao 
and Tavis, 2005), and human immunodeﬁciency virus (HIV) infections (Segat et al., 
2006), hence selected for the current study. 
4.9.1 Detection of IL18 -607 Single Nucleotide Polymorphism 
Genomic DNA was extracted from the blood samples of 120 Healthy controls and 
140 chronic HCV patients. The extracted DNA was amplified by amplification refractory 
mutation system polymerase chain reaction (ARMS-PCR). There were used two sets of 
primers. One set of primer amplified 300-bp product and was used as internal control to 
validate the PCR reaction. The other set of primer was allele specific for IL18 607 and 
amplified 196-bp product. The amplified product was run on 2% agarose gel and 
observed under UV light of gel documentation system to analyze genetic polymorphism 
of the studied subjects (Figure 4.20). 
 
 
 
 
 
 
 
Figure 4.20: Demographic representation of IL18 607 ARMS-PCR amplified products. Lane 
M shows 100-bp ladder. Lane 1 and 2 show heterozygous individual while lane 3 and 4 represent 
homozygous individual for IL18 -607 polymorphism. 
 
Chapter 4  Results 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  92 
 
4.9.2 Distribution of IL18 -607 Genotypes in Healthy Controls and Chronic HCV 
patients 
IL18 gene polymorphism was studied in 120 healthy individuals and 140 chronic 
HCV patients. Regarding, IL18 rs1946518 gene polymorphisms; there were total 87, 113 
and 60 individuals for CC, CA and AA genotypes. All the individuals were divided into 
three groups, healthy controls, SVRs and NRs. The distributions of genotypes were 
according to Hardy-Weinberg principle in all three groups. The frequency of IL18 -607 
genotypes; CC, CA, AA in healthy controls and patients was 32 (27%), 53 (44%), 35 
(29%) and 45 (39%), 60 (43%), 25 (18%) respectively (Figure 4.21). These Figures 
showed that the distribution of IL18 -607 genotypes in the healthy controls and chronic 
HCV patients were comparable suggesting that this polymorphism possessed no role in 
spontaneous clearance of HCV infection in Pakistani patients. 
 
 
 
 
 
  
 
Figure 4.21: Percentage distribution of IL18 -607 polymorphism in healthy controls and 
chronic hepatitis C patients. The prevalence of IL18 -607 genotypes CC, CA and AA in healthy 
controls and chronic HCV patients was; 27%, 44%, 29% and 39%, 43%, 18% respectively. 
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4.9.3 Frequency of IL18 -607 genotypes in SVR and NR groups. 
The distribution frequency of IL18 -607 genotypes; CC, CA, AA in treatment 
responders and non-responders group of chronic HCV patients was; 44 (38%), 47 (41%), 
24 (21%) and 11 (44%), 13 (52%), 1 (4%). To explore the association of any genotype of 
IL18 -607 with interferon based therapy of HCV infection, Pearson chi square test was 
applied. The analysis showed that there were no significant differences in the two groups 
for the distribution of CC and CA genotypes. However, the distribution of AA genotypes 
in SVR group was significantly than NR group (P=0.046), (Figure 4.22). Thus, IL18 -607 
SNP is positively associated with interferon based therapy of HCV infection in Pakistani 
population. 
 
 
 
 
 
 
 
 
 
Figure 4.22: Percentage distribution and P-values of IL18 -607 in responder and non-
responders. P-values for genetic variation in responder and non-responder groups were 
calculated by Pearson chi square test. The P-values for IL18 -607 genotypes; CC, CA and AA 
were 0.594, 0.308 and 0.046 respectively. 
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4.10 DETECTION OF IL18 -137 POLYMORPHISM 
IL18 -137 SNP was identified by ARMS-PCR. Genomic DNA was extracted 
from the whole blood of 120 healthy controls and 140 chronic HCV patients. The 
extracted DNA was amplified by ARMS-PCR using two set of primers. One set of primer 
that amplified 446-bp product was used as internal control to validate the PCR reaction. 
the other set of primer was specific for the amplification of 261-bp product of IL18 -607 
SNP. The amplified product was run on 2% agarose gel along with 50-bp ladder and 
observed by gel documentation system (Figure 4.23). 
 
 
 
 
 
 
 
 
 
Figure 4.23: Digital print out of gel representing ARMS-PCR of IL18 -137. Lane M 
represents 50-bp marker. Lane 1 and 2 represent homozygous individual while lane 3 and 4 
represent heterozygous individual for IL18 -137 polymorphism. 
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4.10.1 Distribution of IL18 -137 Genotypes in Healthy Controls and Chronic HCV 
Patients  
The distribution of IL18 -607 genotypes; GG, GC, CC in healthy controls and 
chronic HCV patients was 43 (36%), 61 (51%), 16 (13%) and 57 (41%), 60 (50%), 13 
(9%) respectively (Figure 4.24). The distribution of all the genotypes in the two groups 
was almost similar. Pearson chi square analysis of the data showed that the P values for 
all these genotypes were greater than 0.05 suggesting that there is no role of these 
genotypes in the natural clearance of HCV infection.  
 
 
 
 
 
 
 
 
Figure 4.24: Percentage distribution of IL18 -137 polymorphism in healthy controls and 
chronic hepatitis C patients. The prevalence of IL18 -137 genotypes; GG, GC, CC in healthy 
controls and chronic HCV patients was 36%, 51%, 13% and 41%, 50%, 9% respectively. The 
prevalence of IL18 -137 genotypes were comparable in healthy controls and chronic HCV 
patients. 
 
 
 
Chapter 4  Results 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  96 
 
4.10.2 Distribution of IL18 -137 Genotypes in SVR and NR groups 
To reveal any correlation of IL18 -137 genotypes with interferon based therapy of 
HCV infection, all patients were catagorized into SVR and NR group. The prevalence of 
IL18 -137 genotypes was observed in both groups. The results suggest that the 
distribution of IL18 -137 genotypes; GG, GC, CC in SVR and NR group was 48 (42%), 
57 (49%), 10 (9%) and 9 (36%), 13 (52%), 3 (12%) respectively (Figure 4.25). Pearson 
chi square test was applied to find the influence of IL18 -137 genotypes on interferon 
based therapy of HCV infection. P values for all the genotypes were greater than 0.05. 
Thus, IL18 -137 polymorphism has no association with the interferon based therapy of 
HCV infection in the current study. 
 
 
 
 
 
 
 
 
 
Figure 4.25: Percentage distribution and P-values of IL18 -137 in responders and non-
responders. The P-values were calculated by Pearson chi square test. The P-values for IL18 -137 
genotypes; GG, GC and CC in treatment responder and non-responder groups were 0.597, 0.825, 
and 0.606 respectively. 
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4.11 DETECTION OF OSTEOPONTIN -442 POLYMORPHISM 
Osteopontin (OPN) is an extracullar matrix mainly produced by bone and kidney. 
It has a wide range of biological activities which involve cell adhesion, proliferation and 
migration (Giachelli and Steitz, 2000; Sodek et al., 2000). Recently, the role of OPN 
promoter polymorphism in HCV infection has been investigated. It was found that 
elevated levels of OPN mRNA and protein expression were associated with 
hepatocellular carcinoma (Huang et al., 2010). The influence of OPN promoter 
polymorphism -442 on natural clearance and interferon based therapy of HCV infection 
was noted in the current study. Genomic DNA was extracted from the whole blood of all 
subjects according to kit protocol. Extracted DNA was amplified by a set allele specific 
primers. The amplified product (442-bp) was run on 2% agarose gel with 50-bp ladder 
and observed under UV light of gel documentation system as shown in Figure 4.26. 
 
 
 
 
 
 
 
 
Figure 4.26: AS-PCR amplification of osteopontin -442 polymorphism of two subjects. Lane 
M specifies 50-bp ladder. Lane 1, 2 5 and 6 specify two heterozygous subjects while lane 4 and 5 
specify homozygous subject for OPN -442 polymorphism. 
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4.11.1 Distribution of Osteopontin -442 Polymorphism in Healthy Controls and 
Chronic HCV Patients 
The distribution of OPN -442 genotypes; CC, CT, TT in 120 healthy controls and 
140 chronic HCV patients was 27 (22.5%), 52 (43.3%), 41 (34.1%) and 26 (18.5%), 66 
(47.1%), 48 (34.2%) respectively (Figure 4.27). Pearson chi square analysis of the data 
showed that the P values of all the genotypes were greater than 0.05. Hence, there was no 
association of any OPN genotype with natural clearance of HCV infection in the present 
study. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Variations in distribution of osteopontin -442 polymorphism in healthy 
controls and chronic hepatitis C patients. The frequency of OPN -442 genotypes; CC, CT and 
TT in healthy controls was 22.5%, 43.3%, and 34.1% respectively. The distribution of 
osteopontin -442 genotypes; CC, CT and TT in chronic HCV patients was 18.5%, 47.1%, and 
34.2% respectively.  
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4.11.2 Distribution of Osteopontin -442 Polymorphism in SVRs and NRs 
The current results suggest that the frequency of OPN -442 genotypes; CC, CT, 
TT in responder and non- responder group was 20 (18%), 51 (44%), 44 (38%) and 6 
(24%), 15 (60%), 4 (16%) respectively. The distribution of all the genotypes in both 
groups was according to Hardy-weinberg equilibrium. To explore the influence of OPN 
polymorphism on interferon therapy of HCV infection, Pearson chi square test was 
applied. There were no significant differences in distributions of OPN GG and CG 
genotypes. However, the P value for OPN CC genotype was significant i.e. 0.034 
(Figure: 4.28). Thus, the results suggest that OPN TT genotype was positively associated 
with interferon based therapy of HCV infection in Pakistani population. 
 
 
 
 
 
 
 
 
Figure 4.28: Comparison of percentage variation of osteopontin -442 polymorphism in 
responders and non-responders. The P values were calculated by Pearson chi square analysis. 
The P values in SVR and NR group for OPN -442 genotypes; CC, CT and TT were 0.441, 0.155 
and 0.034 respectively. 
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4.12 DETECTION OF GALNT8 GENE POLYMORPHISM 
Probable polypeptide N-acetylgalactosaminyltransferase 8 (GALNT8) catalyzes 
the initial reaction in O-linked oligosaccharide biosynthesis. SNP in intron 6 of this 
enzyme at position, rs10849138 is shown to be involved in response to interferon based 
therapy of HCV infection in the Japanese population (Nakano et al., 2013). The 
association of genetic variation of GALNT8 (rs10849138) in healthy controls and chronic 
HCV patients with natural clearance and treatment outcomes of HCV infection was 
considered in Pakistani population. 
Genomic DNA was extracted from the whole blood of all studied subjects. The 
extracted DNA was amplified by a set of allele specific primer. The amplified product 
(340-bp) was run on 2% agarose gel along with 100-bp ladder and observed under UV 
light of gel documentation system (Figure 4.29). 
 
 
 
 
 
 
 
Figure 4.29: Agarose gel represting AS-PCR amplification of GALNT8 gene for three 
individuals. Lane M demonstrates 50-bp ladder. Lane 1 and 2 demonstrate homozygous 
individual while lane 3, 4, 5 and 6 demonstrate heterozygous individual for GALNT8 
polymorphism. 
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4.12.1 Distribution of GALNT8 Polymorphism in Healthy and Patient Groups 
The distribution of GALNT8 genotypes in healthy controls and patients followed 
Hardy-Weinberg equilibrium. The frequency of GALNT8 genotypes; CC, GC, GG in 120 
healthy controls and 140 chronic HCV patients was 31 (25.8%), 64 (53.3%), 25 (20.8%) 
and 32 (22.8%), 59 (49.2%), 39 (27.8%) respectively (Figure 4.30). There were no 
significant differences in prevalence of GALNT8 polymorphism in healthy controls and 
chronic HCV patients. Pearson chi square test showed that P value of all genotypes were 
greater than 0.05. Thus, GALNT8 genotypes have no role in natural clearance of HCV 
infection. 
 
 
 
 
 
 
 
 
 
Figure 4.30: Percentage variation in prevalence of GALNT8 polymorphism in healthy 
individuals and chronic HCV patients. The occurrence of GALNT8 genotypes; CC, CG and 
GG in healthy controls was 25.8%, 53.3% and 20.8% respectively. The distribution of GALNT8 
genotypes; CC, CG and GG in chronic HCV patients was 22.8%, 49.2% and 27.8% respectively. 
 
Chapter 4  Results 
Role of viral and host factors in treatment outcomes of interferon based therapy in chronic HCV Pakistani patients  102 
 
4.12.2 Distribution of GALNT8 polymorphism in SVR and NR groups 
To explore any correlation of GALNT8 gene polymorphism with interferon therapy of 
HCV infection, the prevalence of GALNT8 genotypes were studied in both responders 
and non-responders group. Our results suggest that prevalence of GALNT8 genotypes; 
CC, GC, GG in responders group and non responders group was; 25 (21%), 57 (50%), 33 
(29%) and 7 (28%), 12 (48%), 6 (24%) respectively. Pearson chi square test showed that 
P-values for CC, GC and GG genotypes of GALNT8 genotypes were; 0.499, 0.887 and 
0.635 respectively (Figure 4.31). These values showed that there was no association of 
any genotype of GALNT8 with interferon based therapy of HCV infection in the current 
study.  
 
 
 
 
 
 
 
 
 
Figure 4.31: Percentage distribution of GALNT8 Intron 6 polymorphism in SVRs and NRs. 
The P-values for treatment responder and non-responder groups were calculated by Pearson chi 
square test. The P-values for GALNT8 genotypes CC, CG and GG were; 0.499, 0.887 and 0.635 
respectively. 
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Table 4.2: Statiscal analysis of different genestic variations in response to interferon 
based therapy of HCV infection. 
Genotype 
 
Total (260) Control 
(120) 
SVR (115) NR (25) *P-value 
IL28B rs12979860 genotype 
CC 99 (38.07%) 48 47 4 0.019 
CT 126 (48.4%) 58 53 15 0.207 
TT 35 (13.4%) 14 15 6 0.164 
IL28B rs8099917 genotype 
TT 86 (33%) 39 41 6 0.264 
TG 132 (50.7%) 64 55 13 0.705 
GG 42 (16.1%) 17 19 6 0.376 
TGFβ polymorphism at codon 10 
TT 80 (30.6%) 34 38 8 0.920 
CT 140 (53.8%) 66 62 12 0.591 
CC 40 (15.3%) 20 15 5 0.368 
TGFβ polymorphism at codon 25 
GG 124 (47.6%) 55 59 10 0.306 
GC 101 (38.8%) 48 44 9 0.833 
CC 35 (13.4%) 17 12 6 0.066 
OAS1 polymorphism at,  rs10774671 
GG 125 (48%) 74 84 13 0.039 
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AG 108 (41.5%) 40 26 9 0.161 
AA 27 (10.3%) 6 5 3 0.135 
IL18 -607 polymorphism 
CC 87 (33.4%) 32 44 11 0.594 
CA 113 (43.4%) 53 47 13 0.308 
AA 60 (23%) 35 24 1 0.046 
IL18 -137 polymorphism 
GG 100 (38.4%) 43 48 9 0.597 
GC 131 (50.3%) 61 57 13 0.825 
CC 29 (11.1%) 16 10 3 0.606 
Osteopontin -442  polymorphism 
CC 53 (20.5%) 27 20 6 0.441 
CT 118 (45.3%) 52 51 15 0.155 
TT 89 (34.2 %) 41 44 4 0.034 
GALNT8 polymorphism in intron 6 at rs10849138 
CC 63 (24.2%) 31 25 7 0.499 
GC 133 (51.1%) 64 57 12 0.887 
GG 64 (24.6%) 25 33 6 0.635 
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Chapter 5 
DISCUSSION 
Pakistan is the sixth largest country of the world by population that is situated in 
South Asia. It has four provinces. KPK and Sindh are the two provinces that were 
selected for blood sample collection of chronic HCV infected patients. In Pakistan more 
than 10 million people are infected by HCV that comprise almost 6% of the total 
population (Idrees et al., 2008). Interferon based therapy of HCV infection is well known 
as a standard of care for HCV infection worldwide. However, interferon based therapy of 
HCV infection is associated with both serious side effects and cost effects. It has always 
been an exigent task to envisage the possible outcomes of treatment in HCV infected 
patients. Therefore, precise prediction of patient’s response to therapy is becoming 
important both from patient point of care and treatment cost as well.  
Initially, only baseline viral load of and HCV genotypes were considered as 
potential predictive markers in determining the treatment outcomes and duration of  HCV 
therapy (Fried, 2002; Ghany et al., 2009, Mccaughan et al., 2007; Zeuzem et al., 2009). 
Recently, the discovery of IL28B SNPs and their role in interferon based therapy of HCV 
infection result in their addition to the treatment guidelines by European Association for 
the Study of the Liver (EASL) and the American Association for the Study of Liver 
Diseases (AASL) (Ghany et  al., 2009). The distribution of SNPs and their potential roles 
in natural clearance and treatment outcomes of a disease varies from population to 
population (Rauch et al., 2010; Mchutchison, 2011). Therefore, the present study was 
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designed to evaluate the potential role of HCV genotypes, baseline viral titer and host 
SNPs in interferon based therapy of HCV infection. 
The results suggest that the most common genotype of IL28B rs12979860 was; 
CT (n = 99; 38.07%) followed by CC (n = 126; 48.4%) and TT (n = 35; 13.4%) in the 
present study. The prevalence of IL28B rs12979860 genotypes in healthy controls and 
patients group was almost similar. The presence of IL28B rs12979860CC genotype was 
favorably associated with interferon based therapy of HCV infection. The percentage of 
patients possessing successful fate of treatment was higher in patients with IL28B 
rs12979860CC genotype than TT or CT genotype at this position (P value = 0.019). The 
published data from different ethnic groups throughout the world has established the 
critical role of IL28B rs12979860 polymorphism in the treatment outcomes of HCV 
infection (Rauch et al., 2010; Mchutchison, 2011).  A noteworthy difference in response 
rate to interferon based therapy of HCV infection in African-Americans and European 
individuals has been reported. One of the major reasons for this difference in response 
rate is attributed to unequal distribution of IL28B rs12979860 genotypes in these cohorts. 
The prevalence of IL28B rs12979860CC was more common in individuals from 
European ancestry than individuals from African-Americans. Therefore, Europeans are 
better responders to interferon based therapy of HCV infection. Moreover, it was further 
found that individuals from East Asian ancestry were even better responders to interferon 
based therapy than European ancestor individuals (Yan et al., 2008). Iran from the 
Middle East and India from the South Asia, are the two close neighbor countries of 
Pakistan. In these two countries HCV genotype 3 is one of the most prevalent genotype. 
The reports from these two countries also demonstrated the high prevalence of IL28B 
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rs12979860CC in their population. Furthermore, IL28B rs12979860CC genotype was 
also demonstrated to hold a positive association with interferon based therapy of HCV 
infection, supporting the current results demonstrating the high prevalence and favorable 
role of IL28B rs12979860CC in interferon based therapy of HCV infection (Sharafi et 
al., 2012; Sivaprasad et al., 2012).  
  The present study revealed that regarding IL28B rs8099917 polymorphism, the 
most common genotype was TG (n = 132; 50.7%) followed by TT (n = 86; 33%) and GG 
(n = 42; 16.1%). The distribution of IL28B rs8099917 genotypes in healthy control and 
patient groups was similar. The prevalence of IL28B rs8099917 polymorphism in 
sustained virological responders (SVRs) and non-responders (NRs) was also comparable. 
Worldwide studies have shown a positive association of IL28B rs8099917TT genotype 
with interferon based therapy of HCV infection. These studies were mostly conducted 
against HCV genotype 1 and 4, and less data is available for genotype 3 (Antaki et al., 
2013; Fischer et al., 2012). The reported data suggest that the treatment response rate of 
IL28B rs8099917 of HCV infection is mostly dependent on HCV genotype (Jia et al., 
2012). The current results showed no association between rs8099917TT and treatment 
response of HCV infection. The most probable reason for this lack of association may be 
attributed to the high prevalence of HCV genotype 3 in the current study (71.4%). A 
report from Moghaddam et al., (2011) presented that IL28B rs8099917TT is initially 
associated with enhanced virological response against genotype 3 but later on the 
response was not sustained. Finally, there was no association between IL28B 
rs8099917TT and the treatment response to HCV genotype  3 (Moghaddam et al., 2011). 
Another study also demonstrated a lack of association between IL28B rs8099917TT and 
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the treatment response of HCV genotype 3, but the same study showed an association 
between IL28B rs12979860CC with the response to interferon based therapy against 
HCV genotype 3 (Sarrazin et al., 2010). 
Transforming growth factor beta (TGFβ) is an important cytokine that controls 
cell proliferation and differentiation. Its critical role has been suggested in various 
diseases such as diabetes, heart disease, marfan syndrome and AIDS (Epstein et al., 
2000). Accelerated production of TGFβ is associated with enhanced liver fibrosis 
(Kimura et al., 2006). HCV core protein is reported to stimulate the production of TGFβ 
(Taniguchi et al., 2004). Genetic variations at codon 10 and 25 of TGFβ are shown to 
play a significant role in accelerated liver fibrosis. (Gewaltig et al., 2002; Osterreicher et 
al., 2005).   
 Codon 10 polymorphism of TGFβ was reported to have a role in export 
efficiency of newly synthesized protein (Grainger et al., 1999). Moreover, codon 25 
polymorphism of TGFβ was shown to play a role in graft rejection after liver 
transplantation (Eurich et al., 2011). It was proposed that these two SNPs of TGFβ may 
have a role in treatment outcomes of interferon based therapy of HCV infection. 
However, no association was found for both genotypes of TGFβ polymorphisms with 
treatment outcomes of HCV infection. The current results suggest that there were no 
significant differences in the distribution of both genotypes of TGFβ polymorphisms in 
healthy controls and patients group. The distribution of TGFβ genotypes between 
responder and non-responder groups was also comparable. TGFβ genotypes at codon 10 
and 25 showed no association with interferon based therapy of HCV infection. 
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2'-5' oligoadenylate synthetase 1 (OAS1) gene is critically involved in the 
interferon signaling pathway. Its homolog in mice is reported for predisposition against 
flaviviruses (Mashimo et al., 2008). Findings of current study have shown a significant 
association between polymorphism at exon 7 SAS and interferon based therapy of HCV 
infection. Previously, it was demonstrated by El-Awady et al., (2011) that there is an 
important association between OAS1 polymorphism and the treatment outcomes of HCV 
infection. The present results suggest that patients possessing OAS1GG genotype at exon 
7 SAS showed more sustained virological response than patients possessing either GA or 
AA genotypes (P value = 0.039 vs 0.161 and 0.135 respectively). Thus, patients 
possessing "G" allele at this particular position of OAS1 gene seem to confer better 
treatment response to HCV infection.  Previous studies reported that "G" allele exon 7 
SAS of OAS1 enzyme provides better functional capabilities. The current findings 
confirm the earlier reports that "G" allele at exon 7 SAS of OAS1 gene is linked with 
enhanced enzyme activity. On the contrary, "A" allele at this position provides higher 
molecular weight but a lower enzyme activity (El Awady et al., 2011). 
IL18 is a pro-inflammatory cytokine that encompasses six exons with five introns 
on chromosome 11q22.2-q22.3 (Kruse et al., 2003). The results suggest that promoter 
polymorphism of IL18 -607 is significantly involved in the outcomes of interferon based 
therapy of HCV infection. This is in agreement with previous studies that revealed a 
significant association of promoter polymorphisms of IL18 -607 with natural clearance 
and treatment outcomes of various infectious diseases, (Sivalingam et al., 2003; Gracie et 
al., 2005) and atopic eczema (Novak et al., 2005; Kretowski et al., 2002; Ide et al., 
2004).  The two promoter polymorphisms of IL18 at position -607 and -137 were 
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considered for their association with HCV pathogensis and treatment outcomes. IL18 -
607 showed a significant association with interferon based therapy of HCV infection. The 
current results suggest that individuals possessing AA genotype for IL18 -607 have a 
higher rate of successful treatment outcomes than individuals possessing CC and CA 
genotypes. A study from Egypt has shown that the prevalence of IL18 -607AA genotype 
was higher in healthy controls than patients group suggesting a protective role of this 
genotype against HCV infection (Farid et al., 2013). Another report from India has 
shown that IL18 -607AA genotype is associated with milder liver disease in case of 
chronic HCV patients (Manohar et al., 2009). In the current a significant difference in the 
distribution of -607AA genotype in healthy control and patient groups was found (P = 
0.031). Therefore, according to the current results the prevalence of IL18 -607AA was 
significantly higher in SVRs group than NRs group (P = 0.046). Thus, individuals with 
IL18 -607AA genotype were better responders to combinational therapy of HCV 
infection than individuals possessing other genotypes.  
Regarding IL18 -137 polymorphism, the distribution of IL18 -137 genotypes in 
healthy control and patient groups was comparable. Moreover, the distribution of IL18 -
137 genotypes in treatment responder and non-responder groups was also similar. Thus, 
the current results reveal that IL18 -137 genetic variations possesses neither a role in 
spontaneous clearance of HCV infection nor in treatment response. 
Osteopontin (OPN) also known as sialoprotein is positioned on chromosome 4 
long arm region 13, i.e. 4q13. It comprises of 5 kilobase region with seven exons. SNP at 
OPN -442 was found to have a role in hepatitis activity in chronic HCV patients 
(Mochida et al., 2004). The current results showed that chronic HCV patients with OPN -
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442TT genotypes have a more success rate of combinational therapy than patients 
possessing either CC or CT genotypes (P = 0.034). Thus, OPN -442TT genotype have a 
positive association with the combinational therapy of HCV infection. A study of Naito et 
al., (2005) has shown that OPN polymorphism at -442 can be used as a predictive marker 
for interferon based therapy of HCV infection. The study also showed that SVR rate was 
significantly higher in patients possessing OPN -442TT genotype than any other 
genotype at this position. The results show that there were no significant differences in 
the distributions of OPN -442 genotypes in healthy control and patient groups. Thus, 
OPN -442TT polymorphism appears to have no role in spontaneous clearance of HCV 
infection.  
The association of GALNT8 SNP at rs10849138 with interferon based therapy of 
HCV infection in chronic HCV Pakistani patients was also investigated in the current 
study. The distributions of GALNT8 rs10849138 genotypes in all studied groups i.e. 
healthy controls, chronic HCV patients, treatment responders and non-responder were 
comparable. The current results propose no significant association of any genotype of 
GALNT8 rs10849138 with the natural clearance and interferon based therapy of HCV 
infection. A recent study of Nakano et al., (2013) illustrated an association of GALNT8 
rs2286580 with interferon therapy of HCV infection in the Japanese population. 
However, the results were not repeated in patients receiving peg-interferon and ribavirin 
treatment for HCV infection. The association was at maximum point for GALNT8 
rs10849138 and combinational therapy of HCV infection.  
Regarding HCV-related factors, baseline viral titer and HCV genotypes are  
considered as an independent predictor of SVR but there are suggested several cut-off 
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values for it, depending upon the kit used for viral quantification (Kau et al., 2008). 
Although, there is standardization of viral load to IU/ml, but still it is not possible to 
determine the absolute cut-offs for low and high viral titers. The main reason is that there 
are several commercially available HCV RNA quantification kits that differently 
measures HCV RNA concentrations of the same patient. So therefore, each kit has its 
own cut-offs of low and high viral concentrations (Chevaliez et al., 2007; Michelin et al., 
2007; Sarrazin et al., 2006). The median baseline viral titer of SVR group in the current 
study was; 1.12x10
5 
IU/ml while for NR group, it was 5.64x10
5 
IU/ml. The results 
suggest that although NR group has a high viral titer, but it was statistically not important 
(P = 0.241). Generally the low baseline viral titer is considered to be associated with high 
SVR rate (Ismail et al., 2013). 
There is a significant influence of HCV genotypes on disease severity and 
response to interferon based therapy of HCV infection. Information about HCV 
genotypes is very helpful in the determination of treatment duration and options. 
Generally, patients with HCV genotype 3 are comparatively easy to treat, taking less 
treatment duration and getting a higher rate of SVR. According to the current results, 
HCV subtype 3a was the most common genotype (56.4%). The response rate to 
interferon plus ribavirin treatment of HCV genotype 3 was 91%. These results are in 
parallel with the previous reports showing that HCV genotype 3 is the most prevalent 
genotype in Pakistan with maximum response rate to interferon based therapy (Idrees et 
al., 2008; Ahmad et al., 2012). The second most prevalent HCV genotype was genotype 
1 (13.5%). Treatment response rate to HCV genotype 1 in the present study was 58.5%. 
Worldwide studies have shown that the treatment response rate to HCV genotype 1 is 
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almost 50%. Nine patients in the current study were coinfected. The co-infected patients 
were of genotype 1 and 3 with treatment response rate of 60%. Genotype 4 was the least 
prevalent, only in two patients out of 140. Nine chronic HCV patients were not 
genotyped by the present method of genotyping. Previously a study of Safi et al., (2012) 
also noticed two untypable HCV genotypes from KPK. The mystery of these untypable 
genotypes can be solved by cloning and sequencing of genomic portion of these HCV 
samples. In conclusion, the current study confirms the previous findings that the 
prevalence of HCV genotype 3 was high in chronically HCV infected Pakistani patients 
with a very good response to interferon based therapy of HCV infection. Other HCV 
genotypes, 1 and 2 were less prevalent.  
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST), also 
known as serum glutamic pyruvic transaminase (SGPT) and serum glutamic-oxaloacetic 
transaminase, (SGOT) respectively are transaminases. The elevated levels of ALT and 
AST are the markers of hepatic injury, heart injury or muscle disease. Therefore, these 
enzymes are not liver specific and cannot be used as markers of progression of liver 
fibrosis. In the current study, the baseline level of ALT for responder group was; 
mean±SD: 66.3±33, while for non-responder group it was, mean±SD: 90.3±33.6. The P 
value of independent T test was 0.001. Regarding AST, no significant difference in 
baseline AST levels of responder and non-responder groups was found (72.6±42 vs 
82.5±30; P value = 0.267). Various studies have shown conflicting results about the 
association of baseline levels ALT and AST with interferon based therapy of HCV 
infection (Fried, 2002; Manolakopoulos et al., 2006; Shiﬀman et al., 2007). 
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Alkaline phosphatase is another important liver enzyme which shows liver injury, 
but it is also not specific for hepatic injury. A non-significant difference in baseline ALP 
of responders and non-responder groups was found (311.5.6±143.1 vs 340 ±105.1; P 
value = 0.347). Bilirubin is mainly produced by break down of hemoglobin. Its level is 
also elevated in chronic HCV patients. There were found no significant differences in the 
bilirubin levels of responder and non-responder groups. (1.3±0.87 vs 1.4 ±0.86; P value = 
0.420). 
It is established that young age has an important role in achieving SVR in 
interferon based therapy of HCV infection. Large prospective reports have shown that 
patients younger than forty years are better responders to interferon therapy of HCV 
infection (Poynard et al., 2000; Manns, 2001; Fried, 2002; Shiﬀman et al., 2007). In the 
current study, the mean±SD of the SVR group was 36.28±12.12. The mean±SD for NRs 
group was 37.32±8.24. Thus, mean±SD age of NR group was higher than individual of 
SVR group but independent T test on the data suggest that the difference was not 
statistically significant (P value = 0.608). The summary of the entire study is shown in 
figure 5.1. 
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Figure 5.1. Schematic representation of the study summarizing the results and 
conclusions. 
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In conclusion, these findings constitute the evidence that host SNPs; IL28B 
rs12979860CC genotype, OAS1 rs10774671GG genotype, IL18 -607AA genotype 
(rs1946518), osteopontin -442 CC genotype (rs11730582), low ALT level and HCV 
genotype 3 are all positively associated with  treatment outcomes and may be used as 
predictive markers of interferon based therapy in chronic HCV Pakistani patients. 
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Appendix I: Supplementary material of patients and healthy controls history 
Table representing history of SVR patients 
 
S/N Age Ge
nd
er 
Base line 
viral load 
HCV 
genoty
pe 
IL18 
- 607  
IL18 
-137  
OP
N -
442  
TGF
β 
Codo
n 10  
TGF
β 
Codo
n 25  
GAL
NT8  
1 35 M 210733 3a CC GG CC CT GG GG 
2 40 M 458348 3b CC GG CC CT GG GG 
3 25 M 4384309 3a CA GG TT CT GG GG 
4 28 M 484308 3b AA GC TT CC GC GC 
5 26 M 483489 3a CA GC TT CC GC CC 
6 47 M 848,942 3b CC GC CC CT CC GC 
7 35 F 48,498 3a CC GC TT CC GG GC 
8 22 M 73228 3b CA CC CC CT CC CC 
9 41 M 57439 3a+1b CA CC CT CT CC CC 
10 40 F 905,501 3a CC GC CT TT GC GC 
11 44 M 407,570 3a CA GC TT CT GG GC 
12 22 M 310002 3a CC GG CC CC GG GG 
13 29 M 331057 3a CC GC CC TT GC GC 
14 42 M 678342 1a+3a CA GC TT CT GC GC 
15 33 F 578347 3a CC GG CC CT GG GG 
16 53 M 457825 3b CA GG CT CC GG CC 
17 48 F 748785 3a CC GG TT TT GG GG 
18 31 M 573429 3b CA GC TT TT GC CC 
19 45 F 67487 3a+1b CC GG CC CT GG CC 
20 41 F 547831 3a CC GG CT TT GG GG 
21 47 M 584373 3a CA GC TT TT GC GC 
22 44 M 678489 3b CC GC CT TT GC GC 
23 45 F 473473 3a CA GG TT CT GG GG 
24 41 F 474327 3b CC GC TT TT GC GC 
25 48 F 48482 3a CC GC TT CT GC GC 
26 59 M 55001 3a CC GG CC TT GG GG 
27 46 F 902139 3a CC GC TT CT GC GC 
28 30 F 834874 3a CA GC TT TT GC GC 
29 21 F 484398 1a AA GG CT CT GG GG 
30 48 F 684590 3a CC GC TT TT GG GC 
31 22 F 43832 4 AA GC TT TT GG GC 
32 56 M 498483 3a CC GG CT CT GG GG 
33 44 M 548,741 3a AA GG CT CT GG GG 
34 34 M 5,473,847 3a AA GG CT CT GG GG 
35 34 F 458735 1a+3a AA GC TT CT GC GC 
36 62 F 474387 3a CA GG CT CT GG GG 
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37 29 F 487487 3a CC GG CT CT GG CC 
38 33 M 73488 3a CC GC TT CT GC GC 
39 67 M 85732 1a CA GC TT CT GC GC 
40 29 F 573899 3b CC GG CT CT GG CC 
41 53 M 489458 3a CC GC CT CT GC GC 
42 45 M 94843 3a AA GC CT CT GG GC 
43 57 F 75487 3a CC GG TT CT GG GG 
44 55 M 484589 3a CA GC CC CT GC GC 
45 34 M 458734 3b CC GG CT CT GG GG 
46 30 M 20875 3a CA GC CT CT GC GC 
47 56 M 995433 3a AA GC TT CT GC GC 
48 50 M 67342 3a CA GG CC CT GG GG 
49 34 M 324579 untypea CC GG CT CT GG GG 
50 26 M 984242 3a CA GG CT CT GG GG 
51 40 F 558403 untypea AA GC TT TT GC GC 
52 37 M 584853 3a CA GG TT CT GG CC 
53 33 M 98824 3a CC GG TT CT GG CC 
54 29 M 530248 3b CA GC TT TT GC GC 
55 28 M 32458 3a CC GC CT CT GC CC 
56 27 F 487483 3a CA GG TT CT GG GG 
57 29 M 848438 3a CC GC TT TT GC GC 
58 44 M 484892 3a CA GC CT CT GG GC 
59 59 M 585433 3a AA GC CT TT CC GC 
60 54 M 583442 3a CA GC CC TT GC CC 
61 22 M 78965 3b CC GC TT TT GG GC 
62 30 F 45687 3b AA GC CT CT GC GC 
63 22 F 46698 3a CA CC CT CT CC CC 
64 25 M 36697 1b CC GC CC CT GC GC 
65 22 F 145691 3a CC GG CT TT GG GG 
66 25 M 65894 3a CA GC TT CT GC GC 
67 45 M 45879 1b CC GC CT CT GC CC 
68 60 F 546487 3a CA GG CT TT GG CC 
69 20 F 4578 3a CC GC CT CT GC GC 
70 23 M 45657 3a CA GC CC CC GC GC 
71 26 M 45645 3a CC GC CT TT GC GC 
72 23 M 224567 3b AA GG CT TT GG GG 
73 22 F 77586 1b CA GG CT CT GG GG 
74 25 F 45649 3a CC CC CC CC CC CC 
75 30 M 65784 3a CA GG CT TT GG GG 
76 19 M 89751 3a CA GG CT CC GG GG 
77 35 M 98745 3b CC GC CT CT GC GC 
78 60 M 11456 3a CC GC CT CT CC GC 
79 50 M 204597 3a CA CC TT CT GC GC 
80 20 M 77546 untypea AA GG CT TT GG GG 
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81 21 M 55449 3a CA GC CT CC GG GC 
82 22 M 84454 3a CC GC CC CC GG GC 
83 30 M 76549 3a CA GG CT TT GG CC 
84 35 F 54897 untypea CA GG CT CC GG GG 
85 28 M 644581 3b CC GG TT CT GG CC 
86 25 F 445654 3a CA GC CC CT GC GC 
87 35 M 546989 untypea CA GG CT CC GG GG 
88 22 F 87546 3a AA GG TT CT GG GG 
89 40 F 24568 3b CA CC TT CC GG GC 
90 22 F 55467 3a AA CC CT TT GC GC 
91 45 M 885746 3a CC GG TT TT GG GG 
92 41 M 98745 3a CA GG TT CT GG CC 
93 35 M 65897 untypea AA GG CT CC GC GC 
94 40 M 21465 3a CA GC CT CT GC GC 
95 25 F 5462 1a CA GG CT CT GG GG 
96 37 F 44576 3b AA GG CT CT GG GG 
97 28 M 111249 3a CA GC CC TT GC GC 
98 32 M 44758 3a AA GG TT CT GG GG 
99 26 M 68754 1a CA GC TT TT GC CC 
100 30 F 20457 3a CA CC TT TT GC GC 
101 35 F 980451 3a CC GC CT TT CC GC 
102 28 M 55471 3a+3b AA GG CT CT GG CC 
103 27 F 498754 3a CA GG CT TT GG GC 
104 58 F 44571 1a CA GC CT CT CC GC 
105 50 M 98745 3a CC GC TT TT GC CC 
106 45 F 45475 3a CA GC TT CT GG GC 
107 35 F 98741 4 AA GC CC TT GC GC 
108 23 M 114576 3a CA CC CT CT CC CC 
109 25 M 45769 1a AA GC TT CC GG GC 
110 52 F 58425 1a AA GC CT TT GG CC 
111 25 M 668745 3a CA GC TT TT GC GC 
112 20 M 78956 3a AA GG TT CT CC GC 
113 45 M 75698 1a CC GC CT TT GC GC 
114 65 F 58461 3a+3b AA CC TT CT CC CC 
115 31 M 87549 3a CC GG CC TT GG GC 
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Table representing history of SVR patients 
 
S/N SGPT Biliru
bin 
SGOT Alkaline 
phosphat
ase 
OAS1 
genotype 
IL28B 
rs129798
60 
IL28B 
rs809991
7 
1 51 0.7 45 233 GG CC GG 
2 59 3.7 12 184 AA CC TT 
3 40 0.3 100 220 AG CT TG 
4 107 0.3 95 233 GG CC TG 
5 122 0.6 56 273 AA CT GG 
6 68 1.1 115 250 GG CC TG 
7 72 0.8 151 253 AG CT GG 
8 33 0.6 95 174 GG CT TG 
9 53 0.3 27 233 AG TT TT 
10 37 0.4 133 74 GG CT TG 
11 137 1.1 100 377 AA CC GG 
12 90 0.5 55 212 AG CT TT 
13 29 0.6 41 133 AG CT GG 
14 53 0.6 30 300 AG CC TT 
15 42 0.7 50 467 GG CC TG 
16 43 0.4 65 248 AA CC TG 
17 78 0.6 71 288 AG CC TT 
18 64 0.7 45 148 AA CC TT 
19 74 1.6 75 101 GG CT TG 
20 97 0.3 23 200 AG CT TG 
21 38 2 20 222 GG CC GG 
22 31 2.5 23 432 AA CC TT 
23 23 2 25 300 AG CT GG 
24 40 0.5 56 434 GG CC TT 
25 76 0.9 44 285 AG CT GG 
26 18 3 35 180 AG CT TG 
27 32 0.5 66 201 GG TT TG 
28 74 0.5 75 284 GG CC TG 
29 56 0.6 55 172 GG CT TG 
30 70 1 90 223 AG CT TG 
31 67 0.3 10 615 AG TT TG 
32 27 1 85 574 AG CC TG 
33 70 2 24 300 AG CT TG 
34 30 1.1 45 224 AG CC TG 
35 50 0.9 60 304 AG CC TT 
36 88 0.8 55 243 GG CT TT 
37 59 1.5 50 430 AG CT TT 
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38 65 0.7 70 255 AG TT TT 
39 61 0.7 75 180 GG TT TT 
40 69 1.5 110 301 GG CC GG 
41 23 0.9 15 211 GG CC TG 
42 20 2 55 225 GG CT TG 
43 47 0.4 76 489 AG TT TG 
44 56 0.6 47 278 AG CC TG 
45 38 2.4 78 173 GG CC TT 
46 67 0.7 95 516 AG TT TT 
47 45 0.7 50 638 AG CT GG 
48 98 0.8 60 152 AG TT TT 
49 81 2.5 65 435 GG CC GG 
50 97 3 78 150 AG TT TG 
51 50 0.9 74 201 AG CC GG 
52 98 2.5 45 500 AG CC TT 
53 50 0.5 24 223 AG TT TG 
54 21 1.6 131 399 GG CC GG 
55 160 0.5 66 95 GG TT TT 
56 42 1.3 80 227 GG CT TG 
57 126 1.5 40 235 AA CT TG 
58 70 1.2 25 231 AG CT TG 
59 18 0.6 45 227 AG CC TG 
60 51 1 66 344 GG CT TT 
61 23 0.9 55 114 GG CC TT 
62 65 0.78 182 300 GG CT GG 
63 39 2.5 45 360 AG CC TT 
64 51 1 80 260 AG TT TT 
65 73 0.9 130 400 AG CC TG 
66 99 0.7 68 126 GG TT TG 
67 72 1.7 80 134 AG CT TG 
68 48 2 55 731 AA CC GG 
69 66 2.5 78 93 AG TT TT 
70 25 0.5 200 400 AG CT TT 
71 67 2.3 89 610 AA CC GG 
72 56 4 30 369 GG CC GG 
73 98 3.3 90 150 GG CT TG 
74 56 1.5 87 230 GG CT TG 
75 78 0.9 37 430 AA CT TG 
76 89 2.5 138 320 AG CT TG 
77 45 2.3 35 431 AG CT TG 
78 70 1.7 39 98 GG CT TT 
79 30 0.2 67 330 GG CC TT 
80 38 2.1 100 540 AG CT TT 
81 57 1.1 53 700 AG TT TT 
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82 93 0.97 63 660 GG CT TG 
83 107 0.5 39 340 GG CC TG 
84 65 1.5 89 234 GG CT TG 
85 69 1.1 31 360 AG CC TT 
86 35 1.7 124 479 AG CC TG 
87 55 0.8 128 312 AG CC TG 
88 89 0.6 38 287 GG CC TT 
89 39 2.89 199 345 GG CT TG 
90 105 2.45 62 287 GG CC TG 
91 80 1.3 89 519 GG CC TT 
92 29 0.1 32 402 GG CT TT 
93 44 0.7 85 303 AA CT TG 
94 78 1.3 75 520 GG CT TG 
95 56 1.8 54 89 AA CT TT 
96 231 1.4 79 431 GG CT TG 
97 104 2.4 42 238 GG CC TG 
98 37 0.4 63 342 GG CC TG 
99 89 0.9 213 439 AG CT TT 
100 27 2.1 231 234 AG CT TT 
101 79 0.5 54 340 AG CC TT 
102 88 2.4 76 489 AA CT TT 
103 96 0.8 49 320 AG CT TG 
104 82 1.8 129 210 AG CT TG 
105 83 1.3 143 265 AG CT TG 
106 63 0.67 63 326 AA CC GG 
107 130 0.8 78 279 GG CT TG 
108 91 3.4 86 519 GG CC TT 
109 52 2 29 345 GG CT TG 
110 123 1.34 93 620 AG CT TG 
111 142 2.9 46 320 AG CC TT 
112 42 3.5 86 290 AA CT TT 
113 99 2 145 134 AG CT TG 
114 56 1.8 59 320 AG CT TT 
115 78 1.7 70 390 GG CC GG 
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Appendix II: Table representing history of Non-SVR patients 
 
S/
N 
Ag
e 
G
e
n
d
e
r 
Base 
line 
viral 
load 
HCV 
genoty
pe 
Viral 
load 
after six 
months 
therapy 
IL1
8 - 
607  
IL18
,137 
geno
type 
OP
N -
442  
TGF
β 
Cod
on 
10  
TGF
β 
Cod
on 
25  
GA
LNT
8  
1 28 F 689457 3a+3b 456789 CC GG CT CT GG GC 
2 36 F 897456 1a 759743 CC GG CC CC CC GG 
3 38 M 968751 3a 1193832 AA GG CT CT GG CC 
4 39 M 502347 3b 434409 CA GC CC TT CC GC 
5 29 F 125984 1a 393481 CA GC CT TT GC GC 
6 31 F 158764 1a 232841 CA GC CT CC CC GG 
7 23 F 565946 untypea 753439 CC GC CT TT GC GC 
8 40 M 302598 1a 245389 CA CC CT CC CC CC 
9 37 F 542568 3a+1b 534892 CA CC CT CT CC CC 
10 35 M 984561 3b 288232 CC GC TT CT GC GC 
11 44 F 654879 3a 489284 CA GC CT CC GC CC 
12 46 M 654791 3a 7329382 CC GG CC TT GG GG 
13 51 F 456258 3a+1b 428210 CC GC TT CC GC GC 
14 38 M 958923 3a 739292 CA GC CT CT GG GC 
15 51 M 532659 1a+3a  392398 CC GG CT TT GG CC 
16 32 F 568974 3b 4447221 CA CC CC CT GG CC 
17 35 F 648991 1a 482387 CA GG CT CT GG GG 
18 41 F 987549 3a 487238 CA GC TT TT CC GC 
19 45 F 658457 untypea 848721 CC GG CT CT GG CC 
20 52 M 56644 untypea 4889322 CC GG CC CT GG GG 
21 30 M 145578 3a 3489321 CA GC CC TT GC GC 
22 27 F 564551 1a 4389230 CC GC TT CT GC GC 
23 25 M 44567 3a 39221 CA GG CT CT GG GG 
24 34 F 455987 1b 438921 CC GC CT TT GC GC 
25 46 M 464556 1b 489221 CA GC CT CT GC GC 
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Table representing history of Non-SVR patients 
 
S/N SGPT Bilir
ubin 
SGOT Alkali
ne 
phosp
hatase 
Viral load 
after six 
months 
therapy 
OAS1 
genoty
pe 
IL28B
, 
rs1297
9860 
IL28B, 
rs80999
17 
1 77 1.7 99 311 456789 AG CT TG 
2 45 3.7 91 425 759743 AG CT TG 
3 111 2.3 56 289 1193832 GG CT TT 
4 122 0.9 95 278 434409 AG TT TG 
5 67 0.8 115 273 393481 AA CT TG 
6 131 1.1 95 516 232841 AG CT TT 
7 66 0.8 87 538 753439 AG CT TG 
8 93 2.6 93 190 245389 AG CT TG 
9 123 1.3 145 535 534892 AA CT GG 
10 149 0.4 58 250 288232 GG TT TG 
11 152 3.1 81 280 489284 AG CT GG 
12 59 1.5 70 505 7329382 AG CT TG 
13 98 2.6 150 323 428210 GG CT GG 
14 47 0.6 65 399 739292 AG CC TT 
15 88 1.7 71 195 392398 AG CT GG 
16 142 0.9 45 227 4447221 AA TT GG 
17 117 0.6 75 235 482387 AA CC TG 
18 93 0.9 93 239 487238 AG TT TT 
19 89 2.6 40 327 848721 AG CC TT 
20 81 0.5 43 344 4889322 AG CT TG 
21 63 2 55 414 3489321 AA TT TG 
22 46 2.5 56 380 4389230 AG CT GG 
23 35 2 84 369 39221 AG TT TG 
24 78 0.5 135 260 438921 GG CT TG 
25 87 0.9 66 400 489221 AG CC TT 
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Appendix III: Tables representing features of healthy controls 
 
S/N Ge
nd
er 
Age IL18, 
607 
genot
ype 
IL18
,137 
geno
type 
OP
N -
442  
TGF
β 
Codo
n 10  
TGF
β 
Codo
n 25  
GA
LNT
8  
OAS
1  
IL28
B rs 
1297
9860 
IL28
B 
8009
917 
1 M 28 CC GC CT CT GG CC AG TT TG 
2 M 44 AA CC CC TT CC GG GG CT TG 
3 M 30 CC GC TT CT GC CC AA CC TT 
4 M 30 AA GG CT CT GG CC GG CT TG 
5 F 25 CC GG CC TT CC GC GG TT TG 
6 M 20 AA GC CT CT GG GG GG CT GG 
7 M 40 CC GC TT TT CC GC GG CT TG 
8 M 25 AA GC CC TT GG GC AG TT TT 
9 M 23 CA CC TT CT CC CC GG CT TG 
10 M 28 CA GC CC TT GC GG AA CC TG 
11 F 23 CA GC CT CT GG GC GG CT TT 
12 F 24 CA GG CC TT CC GC GG TT TG 
13 M 29 CA GC TT CT GC GG GG CT TG 
14 F 24 CC CC CC CC GG GC AG CT TG 
15 M 25 CA GC TT CT GG CC AG CT GG 
16 M 24 AA GG TT CC GG GC AG CC TT 
17 M 24 CA GG CC CT GC GG AG CT TG 
18 M 23 CA GG CT CC GC GC AG TT TG 
19 M 23 CC CC TT TT GC GC AG CT TT 
20 M 29 CC GC CC CT GG GG GG CT GG 
21 F 24 CA GC TT TT GG GG AG CC TG 
22 M 24 CC GG CC TT CC GG GG CT TG 
23 M 31 CC CC TT CT GG GC AG CC TT 
24 F 27 CC GC TT TT GG GG GG CC TG 
25 M 35 CA GC TT CC GG GC AG CC TT 
26 M 23 AA GC CT CT GC GG GG CT TG 
27 F 21 AA GC CT CT GC GC GG CT TG 
28 F 21 CA GC CC TT GG GC GG CT TG 
29 F 21 CA GC CT TT CC GC GG CT TG 
30 F 21 CA GC TT CT GC GC GG CT TT 
31 F 21 AA GC CT CC GG GC GG CT TG 
32 M 27 CA CC CT TT CC CC GG CT TG 
33 M 21 AA GC CC TT GC GC AG CT TG 
34 F 22 CC CC CT TT GG CC AG TT TT 
35 F 22 CA GC CT CT GG CC AG TT TG 
36 M 20 AA GG CT CT GG GC GG TT GG 
37 M 18 CA GG CC CT GG GC GG CT TG 
38 M 19 CA GC CT CT GC CC AG CT TG 
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39 F 18 CC GG TT CT CC GC GG CT TG 
40 F 18 CA GG CT TT GC CC AG CT TG 
41 M 18 AA GG TT TT GC GC GG TT TG 
42 M 20 AA GG CT CT CC GG AG CT GG 
43 F 19 AA GC TT CT GG GC AG CT TG 
44 F 19 CA CC CT TT GC GC GG CC TG 
45 F 20 CA GC CT CT GG GC GG CT TT 
46 F 19 CC GC CC TT GC CC GG TT TG 
47 F 18 CA GC CT CT GG GC GG CT TG 
48 F 19 AA GG TT CT GG GC AG CC TT 
49 F 20 CA GG CT CT GG GG GG CT TG 
50 F 18 CA GC CT CC GC CC GG CT TG 
51 F 19 AA GC CC CT GC GC AG CT TG 
52 F 19 CA GC CT CT CC CC GG CT TG 
53 F 19 CA CC CC CC GC CC GG TT TG 
54 F 18 CA GC TT TT GG GC GG CC TG 
55 F 19 AA GC TT CT GC GC GG CT TG 
56 F 19 AA CC CT CC GG GC GG CT TT 
57 M 19 CC GC CC CT GC GC AG CT TG 
58 M 17 AA GC CT TT GG CC AG CC TT 
59 M 18 CA CC CT CT CC GC AG CT TT 
60 F 19 CC GC CC CT CC GC AG CT TG 
61 F 18 CA GG TT CT GC GC GG CC TT 
62 F 19 CA GC CT CT GC CC AG CT TG 
63 F 18 CA GC CT CC GG GC AG CT TT 
64 M 19 CC GC TT CT GG CC AG CT GG 
65 F 19 AA GC TT CC GC CC AA CC TT 
66 F 19 AA CC CC CT GG GC GG CT TG 
67 M 47 CA GC TT CT GG GC AG CT TG 
68 M 37 CA GG CC CT GG GC GG CC GG 
69 M 48 CA GG TT CC GG GG AG CT TG 
70 M 46 CC CC TT CT GG CC AG CT TG 
71 M 34 CA CC TT CT GC GC GG CC TG 
72 M 26 AA GC CT CT CC GC AG CC TT 
73 F 20 CA GG TT TT GC GG GG CT TG 
74 F 20 CA GC TT CT GG GG GG CT TG 
75 F 21 CA GG CT CT GC GC GG CT TG 
76 F 22 CC GG CC CT GC CC GG CT TG 
77 F 22 AA GC CT TT GC GC AG TT TG 
78 F 22 CA GG CT CT CC GC GG TT TG 
79 F 23 CC GC TT CC GC CC GG CT TG 
80 M 23 CA GC TT CT GG GG GG CT TG 
81 F 22 AA GC CT CT GG GC GG CT TG 
82 F 22 CA GG TT CT GG GC GG CC TG 
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83 F 20 CC GG CT CC GC GG AA CT TG 
84 M 20 CA GG CT CT GC GG GG CC TG 
85 M 21 AA GC TT TT GG GG GG CT TG 
86 F 20 CC GG CT TT GG GC GG CC TG 
87 M 21 CA CC CT CT GC GG GG CT TG 
88 M 21 CA GC CT TT GC GC AG CC TG 
89 M 24 CA GG CT CT GC GG GG CC TG 
90 M 19 CA GG CT CT GG GC AA CC GG 
91 M 20 CC GC TT CT CC CC GG CT TG 
92 M 20 CA GG CT CT CC GC GG CT TG 
93 F 19 AA GC CC TT GG CC GG CC TG 
94 F 21 AA GG CC CT GG CC GG CT TG 
95 F 21 CA GC CT CT GG GC AG CT TG 
96 F 20 CA GG CC CT GG GG GG CT TT 
97 M 21 AA GG CT TT GC GC AG CT TG 
98 M 24 CC GC CT CT GC GG GG CC TG 
99 M 29 AA GG CC CC GC CC AG CT TG 
100 M 34 CC GC TT CC GC GC GG CT TG 
101 F 39 AA GG TT CC GC GC GG CC TG 
102 M 23 CC GC TT CT GG GC AA CT TT 
103 M 29 AA CC CT TT GG GC GG CT TG 
104 F 33 CA GC CT CT GC GC GG CC TG 
105 F 25 CC GC TT TT GC CC GG CT TT 
106 F 29 CC GG CC CT GC CC GG CT TT 
107 F 20 CA GC TT CC GG GC AG CT TG 
108 M 40 AA GG CT TT GC CC AG CC TG 
109 F 44 CC GC TT CT GG CC GG CT TT 
110 F 23 AA GG CT CT GG GC GG CT TG 
111 M 45 AA GC CT TT GG GG GG CT TG 
112 M 59 CC GG TT CT GG GC GG CC TG 
113 M 45 CC GG CC CC GC GG GG CC TG 
114 M 33 AA GC CT CC GC CC GG CT TG 
115 M 29 CC GG CC CT GC GC GG CC TG 
116 F 20 CA GC CT TT GG GC AG CT TT 
117 F 29 AA GG CT CT GC GC AG CT TG 
118 F 33 CA GC TT CT GG GC GG CT TT 
119 M 40 CA GG CT TT GC GC GG CT TG 
120 M 43 CC GG TT CC GG CC GG CT TT 
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Appendix IV: List of research and review papers  
Title of research papers published in international journals from PhD dissertation 
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rs12979860, as predictive marker of interferon based therapy in Pakistani population. 
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